multimodal	O
spatiotemporal	O
monitoring	O
of	O
basal	O
stem	O
cellderived	O
organoids	O
reveals	O
progression	O
of	O
olfactory	O
dysfunction	O
in	O
alzheimers	B-NEURODEGENERATIVE
disease	O
olfactory	O
dysfunction	O
od	O
is	O
a	O
highly	O
prevalent	O
symptom	O
and	O
an	O
early	O
sign	O
of	O
neurodegenerative	O
diseases	O
in	O
humans	O
however	O
the	O
roles	O
of	O
peripheral	O
olfactory	O
system	O
in	O
disease	O
progression	O
and	O
the	O
mechanisms	O
behind	O
neurodegeneration	O
remain	O
to	O
be	O
studied	O
olfactory	O
epithelium	O
oe	O
organoid	O
is	O
an	O
ideal	O
model	O
to	O
study	O
pathophysiology	O
in	O
vitro	O
yet	O
the	O
reliance	O
on	O
3d	O
culture	O
condition	O
limits	O
continual	O
in	O
situ	O
monitoring	O
of	O
organoid	O
development	O
here	O
we	O
combined	O
impedance	O
biosensors	O
and	O
live	O
imaging	O
for	O
realtime	O
spatiotemporal	O
analysis	O
of	O
oe	O
organoids	O
morphological	O
and	O
physiological	O
features	O
during	O
alzheimers	B-NEURODEGENERATIVE
disease	O
ad	B-NEURODEGENERATIVE
progression	O
the	O
impedance	O
measurements	O
showed	O
that	O
organoids	O
generated	O
from	O
basal	O
stem	O
cells	O
of	O
appps1	O
transgenic	O
mice	O
had	O
lower	O
proliferation	O
rate	O
than	O
that	O
from	O
wildtype	O
mice	O
in	O
concert	O
with	O
the	O
biosensor	O
measurements	O
live	O
imaging	O
enabled	O
to	O
visualize	O
the	O
spatial	O
and	O
temporal	O
dynamics	O
of	O
organoid	O
morphology	O
abnormal	O
protein	O
aggregation	O
and	O
accumulation	O
including	O
amyloid	O
plaques	O
and	O
neurofibrillary	O
tangles	O
was	O
found	O
in	O
ad	B-NEURODEGENERATIVE
organoids	O
and	O
increased	O
as	O
disease	O
progressed	O
this	O
multimodal	O
in	O
situ	O
bioelectrical	O
measurement	O
and	O
imaging	O
provide	O
a	O
new	O
platform	O
for	O
investigating	O
onset	O
mechanisms	O
of	O
od	O
which	O
would	O
shed	O
new	O
light	O
on	O
early	O
diagnosis	O
and	O
treatment	O
of	O
neurodegenerative	O
disease	O
identifying	O
the	O
potential	O
role	O
of	O
serum	O
mir20a	O
as	O
a	O
biomarker	O
for	O
olfactory	O
dysfunction	O
in	O
patients	B-PERCIEVER
with	O
parkinsons	B-NEURODEGENERATIVE
disease	O
introduction	O
olfactory	O
dysfunction	O
od	O
one	O
of	O
the	O
most	O
common	O
nonmotor	O
symptoms	O
in	O
parkinsons	B-NEURODEGENERATIVE
disease	O
pd	B-NEURODEGENERATIVE
is	O
a	O
cardinal	O
prodromal	O
symptom	O
that	O
can	O
appear	O
years	O
before	O
the	O
onset	O
of	O
motor	O
symptoms	O
ongoing	O
studies	O
have	O
demonstrated	O
that	O
micrornas	O
mirnas	O
are	O
suitable	O
biomarkers	O
for	O
pd	B-NEURODEGENERATIVE
while	O
there	O
is	O
a	O
lack	O
of	O
robust	O
mirnas	O
that	O
can	O
serve	O
as	O
markers	O
for	O
od	O
in	O
pd	B-NEURODEGENERATIVE
methods	O
the	O
concordantly	O
differentially	O
expressed	O
mirnas	O
de	O
mirnas	O
in	O
the	O
damaged	O
olfactory	O
system	O
were	O
first	O
identified	O
in	O
2	O
odrelated	O
gene	O
expression	O
omnibus	O
geo	O
datasets	O
then	O
they	O
were	O
verified	O
in	O
another	O
pdrelated	O
geo	O
dataset	O
and	O
only	O
one	O
mirna	O
mir20a	O
was	O
found	O
to	O
be	O
significantly	O
altered	O
serum	O
levels	O
of	O
mir20a	O
were	O
further	O
measured	O
by	O
qpcr	O
in	O
79	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
with	O
od	O
pdod	O
52	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
without	O
od	O
pdnod	O
and	O
52	O
healthy	O
controls	O
hc	O
objective	O
measure	O
of	O
od	O
was	O
defined	O
by	O
16item	O
sniffin	O
sticks	O
odor	O
identification	O
test	O
all	O
the	O
participants	B-PERCIEVER
underwent	O
a	O
demographic	O
and	O
comprehensive	O
pdrelated	O
clinical	O
assessment	O
results	O
our	O
results	O
proved	O
that	O
mir20a	O
was	O
significantly	O
downregulated	O
in	O
pdod	O
compared	O
with	O
pdnod	O
and	O
the	O
area	O
under	O
curve	O
auc	O
for	O
od	O
detection	O
by	O
mir20a	O
was	O
0803	O
95	O
confidence	O
interval	O
07240883	O
in	O
addition	O
pdod	O
had	O
higher	O
scores	O
of	O
movement	O
disorder	O
societyunified	O
parkinsons	B-NEURODEGENERATIVE
disease	O
rating	O
scale	O
updrs	O
ii	O
hoehn	O
and	O
yahr	O
stage	O
hy	O
nonmotor	O
symptoms	O
scale	O
nmss	O
3	O
nmss	O
5	O
nmss	O
9	O
hamilton	O
rating	O
scale	O
for	O
depression	O
hamd	O
hamilton	O
anxiety	O
scale	O
hama	O
activity	O
of	O
daily	O
living	O
adl	O
and	O
lower	O
scores	O
of	O
minimental	O
state	O
examination	O
mmse	O
and	O
39item	O
pd	B-NEURODEGENERATIVE
quality	O
of	O
life	O
questionnaire	O
pdq39	O
than	O
pdnod	O
binary	O
regression	O
model	O
further	O
presented	O
that	O
lower	O
expressions	O
of	O
mir20a	O
and	O
poorer	O
cognitive	O
function	O
acted	O
as	O
promoting	O
factors	O
in	O
the	O
development	O
of	O
od	O
conclusion	O
our	O
results	O
suggest	O
that	O
mir20a	O
could	O
be	O
a	O
novel	O
biomarker	O
for	O
od	O
in	O
pd	B-NEURODEGENERATIVE
and	O
pdod	O
patients	B-PERCIEVER
tend	O
to	O
have	O
higher	O
disease	O
stage	O
poorer	O
motor	O
aspects	O
of	O
experiences	O
of	O
daily	O
living	O
worse	O
cognitive	O
scores	O
and	O
inferior	O
quality	O
of	O
life	O
and	O
were	O
more	O
likely	O
to	O
have	O
mental	O
disorders	O
cognitive	O
function	O
in	O
particular	O
is	O
strongly	O
associated	O
with	O
od	O
in	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
could	O
covid19	O
anosmia	B-OLFACTORY
and	O
olfactory	O
dysfunction	O
trigger	O
an	O
increased	O
risk	O
of	O
future	O
dementia	B-NEURODEGENERATIVE
in	O
patients	B-PERCIEVER
with	O
apoe4	O
the	O
association	O
of	O
the	O
coronavirus	O
disease	O
2019	O
covid19	O
with	O
significant	O
neurological	O
and	O
neuropsychiatric	O
complications	O
has	O
been	O
increasingly	O
reported	O
both	O
during	O
the	O
acute	O
illness	O
and	O
in	O
its	O
aftermath	O
however	O
due	O
to	O
the	O
short	O
duration	O
of	O
patient	B-PERCIEVER
follow	O
up	O
until	O
now	O
it	O
is	O
not	O
clear	O
whether	O
this	O
infection	O
will	O
be	O
associated	O
with	O
longerterm	O
neurological	O
andor	O
neuropsychiatric	O
sequelae	O
in	O
particular	O
the	O
question	O
of	O
whether	O
covid19	O
will	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
and	O
rate	O
of	O
future	O
dementia	B-NEURODEGENERATIVE
remains	O
open	O
and	O
subject	O
to	O
speculation	O
during	O
the	O
course	O
of	O
the	O
covid19	O
pandemic	O
an	O
increasing	O
number	O
of	O
patients	B-PERCIEVER
have	O
reported	O
sudden	O
anosmia	B-OLFACTORY
or	O
other	O
olfactory	O
dysfunction	O
as	O
concurrent	O
symptoms	O
the	O
possibility	O
that	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
2	O
sarscov2	O
may	O
reach	O
the	O
brain	O
via	O
the	O
olfactory	O
nerve	O
or	O
an	O
upper	O
nasal	O
trancribrial	O
route	O
is	O
an	O
interesting	O
working	O
hypothesis	O
among	O
the	O
identified	O
genetic	O
risk	O
factors	O
for	O
lateonset	O
alzheimers	B-NEURODEGENERATIVE
disease	O
load	O
apo	O
e4	O
is	O
one	O
of	O
the	O
strongest	O
and	O
most	O
frequent	O
people	O
carrying	O
one	O
or	O
two	O
copies	O
of	O
the	O
e4	O
allele	O
of	O
apo	O
e4	O
have	O
significant	O
odor	O
recognition	O
deficits	O
in	O
comparison	O
to	O
those	O
not	O
carrying	O
this	O
haplotype	O
the	O
hypothesis	O
invoked	O
in	O
this	O
paper	O
is	O
that	O
anosmiaolfactory	O
dysfunctions	O
induced	O
by	O
sarscov2	O
may	O
cause	O
an	O
increased	O
a	O
risk	O
of	O
future	O
neurodegenerative	O
dementia	B-NEURODEGENERATIVE
in	O
apoe4	O
carriers	O
and	O
that	O
this	O
risk	O
would	O
be	O
higher	O
than	O
in	O
apo	O
e4	O
carriers	O
affected	O
by	O
anosmia	B-OLFACTORY
not	O
induced	O
by	O
sarscov2	O
this	O
would	O
be	O
associated	O
with	O
virusinduced	O
chronic	O
modifications	O
in	O
the	O
central	O
nervous	O
system	O
it	O
is	O
proposed	O
that	O
covid19	O
patients	B-PERCIEVER
with	O
anosmia	B-OLFACTORY
and	O
no	O
other	O
serious	O
symptoms	O
should	O
be	O
followed	O
up	O
as	O
part	O
of	O
specifically	O
designed	O
and	O
approved	O
studies	O
in	O
order	O
to	O
identify	O
the	O
early	O
stages	O
of	O
dementia	B-NEURODEGENERATIVE
especially	O
load	O
and	O
dementia	B-NEURODEGENERATIVE
with	O
lewy	O
bodies	O
thereby	O
improving	O
our	O
knowledge	O
of	O
the	O
mechanisms	O
involved	O
in	O
precognitive	O
stages	O
of	O
neurodegenerative	O
dementia	B-NEURODEGENERATIVE
and	O
making	O
best	O
use	O
of	O
any	O
available	O
therapies	O
this	O
latter	O
opportunity	O
is	O
unique	O
and	O
should	O
not	O
be	O
lost	O
nicotine	O
increases	O
lifespan	O
and	O
rescues	O
olfactory	O
and	O
motor	O
deficits	O
in	O
a	O
drosophila	O
model	O
of	O
parkinsons	B-NEURODEGENERATIVE
disease	O
drosophila	O
melanogaster	O
is	O
an	O
attractive	O
model	O
of	O
familial	O
parkinsons	B-NEURODEGENERATIVE
disease	O
as	O
flies	O
with	O
lossoffunction	O
mutations	O
of	O
the	O
parkin	O
gene	O
exhibit	O
many	O
pathologies	O
observed	O
in	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
progressive	O
motor	O
deficits	O
found	O
in	O
homozygous	O
parkin	O
mutants	O
seem	O
to	O
result	O
from	O
mitochondrial	O
pathology	O
that	O
causes	O
indirect	O
flight	O
muscle	O
and	O
dopaminergic	O
neuronal	O
degeneration	O
12	O
we	O
have	O
found	O
that	O
heterozygous	O
parkin	O
mutants	O
have	O
decreased	O
lifespan	O
generally	O
progressive	O
motor	O
dysfunction	O
and	O
olfactory	O
deficits	O
compared	O
to	O
control	O
flies	O
suggesting	O
that	O
mutation	O
of	O
this	O
gene	O
produces	O
a	O
dominant	O
phenotype	O
tobacco	O
smokers	O
are	O
dosedependently	O
less	O
likely	O
to	O
develop	O
pd	B-NEURODEGENERATIVE
34	O
subsequent	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
show	O
that	O
nicotine	O
is	O
protective	O
in	O
models	O
of	O
sporadic	O
pd	B-NEURODEGENERATIVE
6	O
literature	O
addressing	O
the	O
potential	O
protection	O
by	O
nicotine	O
in	O
parkin	O
lossoffunction	O
models	O
spans	O
limited	O
concentrations	O
and	O
selected	O
time	O
points	O
in	O
the	O
organisms	O
lifespan	O
we	O
have	O
found	O
that	O
parkin	O
heterozygotes	O
have	O
lateonset	O
climbing	O
and	O
flying	O
deficits	O
as	O
well	O
as	O
decreased	O
viability	O
and	O
olfactory	O
deficits	O
that	O
precede	O
motor	O
defects	O
while	O
chronic	O
nicotine	O
exposure	O
decreases	O
lifespan	O
and	O
climbing	O
and	O
flying	O
abilities	O
in	O
control	O
flies	O
it	O
can	O
improve	O
viability	O
and	O
flying	O
capability	O
as	O
well	O
as	O
rescue	O
climbing	O
and	O
olfactory	O
deficits	O
in	O
parkin	O
heterozygotes	O
dopaminergic	O
neurons	O
are	O
spared	O
in	O
the	O
parkin	O
heterozygote	O
perhaps	O
because	O
this	O
phenotype	O
is	O
less	O
severe	O
than	O
in	O
the	O
homozygous	O
parkin	O
mutants	O
nicotine	O
pretreatment	O
may	O
be	O
protective	O
in	O
sporadic	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
and	O
models	O
however	O
timely	O
diagnosis	O
remains	O
to	O
be	O
an	O
obstacle	O
our	O
results	O
suggest	O
that	O
nicotine	O
also	O
may	O
be	O
protective	O
in	O
familial	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
who	O
can	O
be	O
easily	O
identified	O
before	O
motor	O
symptoms	O
occur	O
olfactory	O
dysfunction	O
is	O
associated	O
with	O
motor	O
function	O
only	O
in	O
tremordominant	O
parkinsons	B-NEURODEGENERATIVE
disease	O
background	O
the	O
prevalence	O
of	O
olfactory	O
impairment	O
in	O
patients	B-PERCIEVER
with	O
parkinsons	B-NEURODEGENERATIVE
disease	O
pd	B-NEURODEGENERATIVE
is	O
5090	O
and	O
therefore	O
olfactory	O
dysfunction	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
nonmotor	O
symptoms	O
nmss	O
in	O
patients	B-PERCIEVER
with	O
pd	B-NEURODEGENERATIVE
numerous	O
studies	O
have	O
evaluated	O
the	O
association	O
between	O
motor	O
and	O
nonmotor	O
symptoms	O
and	O
olfactory	O
dysfunction	O
in	O
pd	B-NEURODEGENERATIVE
aim	O
in	O
this	O
study	O
we	O
investigated	O
the	O
relationship	O
between	O
olfactory	O
dysfunction	O
which	O
is	O
measured	O
using	O
the	O
upsit	B-SMELL_TEST
test	O
with	O
other	O
motor	O
and	O
nonmotor	O
symptoms	O
separately	O
in	O
three	O
motor	O
subtypes	O
of	O
pd	B-NEURODEGENERATIVE
including	O
tremor	O
dominant	O
td	O
postural	O
instability	O
and	O
gait	O
difficulty	O
pigd	O
and	O
indeterminate	O
and	O
healthy	O
subjects	B-PERCIEVER
methods	O
we	O
recruited	O
487	O
earlystage	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
43	O
pigd	O
406	O
td	O
and	O
38	O
indeterminate	O
and	O
healthy	O
controls	O
hcs	O
n	O
197	O
from	O
the	O
parkinson	B-NEURODEGENERATIVE
progression	O
markers	O
initiative	O
ppmi	O
all	O
participants	B-PERCIEVER
completed	O
motor	O
and	O
nonmotor	O
tests	O
at	O
baseline	O
visit	O
and	O
after	O
4	O
years	O
of	O
followup	O
subjects	B-PERCIEVER
underwent	O
common	O
pd	B-NEURODEGENERATIVE
scaling	O
tests	O
results	O
olfactory	O
dysfunction	O
was	O
significantly	O
correlated	O
with	O
declined	O
motor	O
functions	O
only	O
in	O
the	O
td	O
subtype	O
also	O
significant	O
correlations	O
were	O
noticed	O
between	O
olfactory	O
dysfunction	O
and	O
speedattention	O
processing	O
and	O
executive	O
function	O
in	O
the	O
hcs	O
as	O
well	O
finally	O
no	O
significant	O
or	O
meaningful	O
association	O
was	O
observed	O
in	O
the	O
pigd	O
and	O
indeterminate	O
subtype	O
anosmia	B-OLFACTORY
and	O
hyposmia	B-OLFACTORY
subjects	B-PERCIEVER
in	O
the	O
td	O
group	O
had	O
the	O
worse	O
motor	O
and	O
nonmotor	O
scores	O
compared	O
to	O
normosmia	O
subjects	B-PERCIEVER
after	O
4	O
years	O
conclusion	O
olfactory	O
dysfunction	O
was	O
significantly	O
correlated	O
with	O
declined	O
motor	O
functions	O
in	O
the	O
td	O
subtype	O
this	O
is	O
indicating	O
that	O
olfactory	O
dysfunction	O
may	O
be	O
an	O
early	O
motor	O
and	O
nonmotor	O
biomarker	O
only	O
in	O
the	O
td	O
subtype	O
however	O
it	O
is	O
possible	O
that	O
the	O
involvement	O
of	O
olfactory	O
function	O
in	O
other	O
subtypes	O
is	O
not	O
strong	O
enough	O
to	O
make	O
it	O
a	O
useful	O
marker	O
of	O
diseases	O
progression	O
clinical	O
structural	O
and	O
neuropathological	O
features	O
of	O
olfactory	O
dysfunction	O
in	O
patients	B-PERCIEVER
with	O
alzheimers	B-NEURODEGENERATIVE
disease	O
we	O
explored	O
changes	O
in	O
clinical	O
features	O
and	O
neuropathological	O
mechanisms	O
underlying	O
olfactory	O
dysfunction	O
od	O
in	O
60	O
patients	B-PERCIEVER
with	O
alzheimers	B-NEURODEGENERATIVE
disease	O
ad	B-NEURODEGENERATIVE
olfactory	O
function	O
was	O
evaluated	O
using	O
the	O
sniffin	O
sticks	O
test	O
and	O
a	O
threshold	O
discrimination	O
identification	O
tdi	O
score	O
based	O
on	O
the	O
tdi	O
score	O
we	O
divided	O
patients	B-PERCIEVER
according	O
to	O
the	O
presence	O
or	O
absence	O
of	O
od	O
adod	O
and	O
adnod	O
respectively	O
cognitive	O
and	O
neuropsychiatric	O
symptoms	O
were	O
evaluated	O
by	O
a	O
series	O
of	O
rating	O
scales	O
the	O
volumes	O
and	O
cortical	O
thickness	O
of	O
the	O
thalamus	O
hippocampus	O
and	O
amygdala	O
were	O
measured	O
using	O
structural	O
magnetic	O
resonance	O
imaging	O
neuropathological	O
protein	O
levels	O
in	O
cerebrospinal	O
fluid	O
were	O
measured	O
the	O
frequency	O
of	O
od	O
was	O
50	O
tdi	O
scores	O
were	O
lower	O
in	O
the	O
adod	O
group	O
than	O
in	O
the	O
adnod	O
group	O
p	O
0001	O
compared	O
with	O
the	O
adnod	O
group	O
the	O
adod	O
group	O
showed	O
greater	O
cognitive	O
function	O
impairments	O
p	O
0001	O
and	O
daily	O
living	O
activities	O
were	O
more	O
severely	O
compromised	O
p	O
0019	O
the	O
adod	O
group	O
had	O
lower	O
hippocampal	O
and	O
amygdala	O
volumes	O
p	O
0025	O
p	O
0030	O
respectively	O
and	O
a	O
more	O
pronounced	O
reduction	O
in	O
cortical	O
thickness	O
p	O
0010	O
the	O
total	O
tau	O
level	O
was	O
lower	O
in	O
the	O
adod	O
group	O
than	O
the	O
adnod	O
group	O
p	O
0040	O
lower	O
minimental	O
state	O
examination	O
scores	O
and	O
thinner	O
adsignature	O
cortices	O
were	O
associated	O
with	O
lower	O
tdi	O
scores	O
or	O
0826	O
p	O
0001	O
or	O
1433	O
p	O
0008	O
overall	O
in	O
ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER
the	O
impairments	O
in	O
olfactory	O
discrimination	O
and	O
identification	O
seem	O
to	O
be	O
more	O
correlated	O
with	O
cognitive	O
levels	O
od	O
in	O
ad	B-NEURODEGENERATIVE
may	O
be	O
an	O
indicator	O
of	O
pathological	O
cognitive	O
decline	O
and	O
structural	O
changes	O
impairment	O
of	O
odor	O
recognition	O
in	O
myotonic	O
dystrophy	O
type	O
1	O
there	O
is	O
evidence	O
that	O
impaired	O
human	B-PERCIEVER
cognitive	O
abilities	O
are	O
reflected	O
in	O
loss	O
of	O
olfactory	O
abilities	O
declining	O
olfactory	O
perception	O
may	O
be	O
a	O
biomarker	O
for	O
impairment	O
of	O
cognitive	O
function	O
and	O
of	O
impending	O
illnesses	O
in	O
neurodegenerative	O
disorders	O
such	O
as	O
parkinsons	B-NEURODEGENERATIVE
disease	O
pd	B-NEURODEGENERATIVE
and	O
alzheimers	B-NEURODEGENERATIVE
disease	O
ad	B-NEURODEGENERATIVE
previously	O
we	O
reported	O
that	O
patients	B-PERCIEVER
with	O
myotonic	O
dystrophy	O
type	O
1	O
dm	O
1	O
had	O
lower	O
sensitivity	O
to	O
emotional	O
facial	O
expressions	O
as	O
well	O
as	O
abnormal	O
olfactory	O
threshold	O
or	O
recognition	O
level	O
in	O
dm	O
1	O
pathological	O
studies	O
have	O
reported	O
neurofibrillary	O
tangles	O
in	O
several	O
temporal	O
areas	O
including	O
the	O
entorhinal	O
cortex	O
ent	O
hippocampus	O
hi	O
and	O
the	O
amygdala	O
we	O
observed	O
that	O
patients	B-PERCIEVER
with	O
dm	O
1	O
showed	O
signal	O
abnormalities	O
in	O
the	O
olfactory	O
limbic	O
areas	O
on	O
magnetic	O
resonance	O
imaging	O
our	O
findings	O
underscore	O
the	O
need	O
to	O
pay	O
careful	O
attention	O
to	O
significant	O
decreases	O
in	O
odor	O
identification	O
abilities	O
caused	O
by	O
diverse	O
forms	O
of	O
abnormal	O
brain	O
function	O
especially	O
in	O
the	O
amg	O
ent	O
and	O
hi	O
olfactory	O
testing	O
does	O
not	O
predict	O
betaamyloid	O
mri	O
measures	O
of	O
neurodegeneration	O
or	O
vascular	O
pathology	O
in	O
the	O
british	O
1946	O
birth	O
cohort	O
objective	O
to	O
explore	O
the	O
value	O
of	O
olfactory	O
identification	O
deficits	O
as	O
a	O
predictor	O
of	O
cerebral	O
betaamyloid	O
status	O
and	O
other	O
markers	O
of	O
brain	O
health	O
in	O
cognitively	O
normal	O
adults	O
aged	O
70	O
years	O
methods	O
crosssectional	O
observational	O
cohort	O
study	O
389	O
largely	O
healthy	O
and	O
cognitively	O
normal	O
older	O
adults	O
were	O
recruited	O
from	O
the	O
mrc	O
national	O
survey	O
of	O
health	O
and	O
development	O
1946	O
british	O
birth	O
cohort	O
and	O
investigated	O
for	O
olfactory	O
identification	O
deficits	O
as	O
measured	O
by	O
the	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O
outcome	O
measures	O
were	O
imaging	O
markers	O
of	O
brain	O
health	O
derived	O
from	O
3	O
t	O
mri	O
scanning	O
cortical	O
thickness	O
entorhinal	O
cortex	O
thickness	O
white	O
matter	O
hyperintensity	O
volumes	O
18f	O
florbetapir	O
amyloidpet	O
scanning	O
and	O
cognitive	O
testing	O
results	O
participants	B-PERCIEVER
were	O
assessed	O
at	O
a	O
single	O
centre	O
between	O
march	O
2015	O
and	O
january	O
2018	O
results	O
mean	O
sd	O
age	O
was	O
706	O
07	O
years	O
508	O
were	O
female	B-PERCIEVER
645	O
had	O
hyposmia	B-OLFACTORY
and	O
26	O
anosmia	B-OLFACTORY
olfaction	O
showed	O
no	O
association	O
with	O
betaamyloid	O
status	O
hippocampal	O
volume	O
entorhinal	O
cortex	O
thickness	O
ad	B-NEURODEGENERATIVE
signature	O
cortical	O
thickness	O
white	O
matter	O
hyperintensity	O
volume	O
or	O
cognition	O
conclusion	O
and	O
relevance	O
in	O
the	O
early	O
70s	O
olfactory	O
function	O
is	O
not	O
a	O
reliable	O
predictor	O
of	O
a	O
range	O
of	O
imaging	O
and	O
cognitive	O
measures	O
of	O
preclinical	O
ad	B-NEURODEGENERATIVE
olfactory	O
identification	O
deficits	O
are	O
not	O
likely	O
to	O
be	O
a	O
useful	O
means	O
of	O
identifying	O
asymptomatic	O
amyloidosis	O
further	O
studies	O
are	O
required	O
to	O
assess	O
if	O
change	O
in	O
olfaction	O
may	O
be	O
a	O
proximity	O
marker	O
for	O
the	O
development	O
of	O
cognitive	O
impairment	O
olfactory	O
erps	O
in	O
an	O
odorvisual	O
congruency	O
task	O
differentiate	O
apoe	O
epsilon4	O
carriers	O
from	O
noncarriers	O
alzheimers	B-NEURODEGENERATIVE
disease	O
ad	B-NEURODEGENERATIVE
is	O
a	O
progressive	O
neurodegenerative	O
disorder	O
that	O
impairs	O
memory	O
and	O
semantic	O
processing	O
ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER
and	O
mci	O
patients	B-PERCIEVER
at	O
risk	O
for	O
ad	B-NEURODEGENERATIVE
show	O
altered	O
n400	O
erp	O
responses	O
to	O
incongruent	O
visual	O
and	O
verbal	O
stimuli	O
ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER
exhibit	O
neuropathology	O
in	O
olfactory	O
brain	O
areas	O
before	O
cognitive	O
symptoms	O
suggesting	O
the	O
potential	O
for	O
olfactory	O
processing	O
to	O
reflect	O
early	O
pathology	O
despite	O
this	O
odor	O
congruency	O
has	O
not	O
been	O
examined	O
we	O
investigated	O
odorimage	O
congruency	O
in	O
older	O
adults	O
at	O
genetic	O
risk	O
for	O
ad	B-NEURODEGENERATIVE
apoe	O
epsilon4	O
carriers	O
and	O
noncarriers	O
were	O
screened	O
for	O
anosmia	B-OLFACTORY
severe	O
hyposmia	B-OLFACTORY
and	O
dementia	B-NEURODEGENERATIVE
olfactory	O
erps	O
were	O
measured	O
6001300	O
ms	B-NEURODEGENERATIVE
following	O
odorimage	O
pairs	O
odors	O
were	O
each	O
presented	O
once	O
congruently	O
and	O
once	O
incongruently	O
via	O
an	O
olfactometer	O
pz	O
amplitude	O
significantly	O
decreased	O
on	O
incongruent	O
trials	O
in	O
e4	O
carriers	O
pz	O
amplitude	O
differences	O
on	O
congruous	O
and	O
incongruous	O
trials	O
were	O
larger	O
in	O
non	O
carriers	O
regression	O
indicated	O
that	O
congruency	O
showed	O
very	O
high	O
sensitivity	O
and	O
specificity	O
for	O
correctly	O
classifying	O
epsilon4	O
carriers	O
from	O
noncarriers	O
rbm24notch1	O
signaling	O
regulates	O
adult	O
neurogenesis	O
in	O
the	O
subventricular	O
zone	O
and	O
mediates	O
parkinsonassociated	O
olfactory	O
dysfunction	O
rationale	O
adult	O
neurogenesis	O
in	O
the	O
subventricular	O
zone	O
svz	O
is	O
essential	O
for	O
maintaining	O
neural	O
homeostasis	O
and	O
its	O
dysregulation	O
contributes	O
to	O
anosmia	B-OLFACTORY
and	O
delayed	O
tissue	O
healing	O
in	O
neurological	O
disorders	O
such	O
as	O
parkinsons	B-NEURODEGENERATIVE
disease	O
pd	B-NEURODEGENERATIVE
despite	O
intricate	O
regulatory	O
networks	O
identified	O
in	O
svz	O
neurogenesis	O
the	O
molecular	O
mechanisms	O
dynamically	O
maintaining	O
neural	O
stemprogenitor	O
cells	O
nspcs	O
in	O
response	O
to	O
physiological	O
and	O
pathological	O
stimuli	O
remain	O
incompletely	O
elucidated	O
methods	O
we	O
generated	O
an	O
rna	O
binding	O
motif	O
protein	O
24	O
rbm24	O
knockout	O
model	O
to	O
investigate	O
its	O
impact	O
on	O
adult	O
neurogenesis	O
in	O
the	O
svz	O
employing	O
immunofluorescence	O
immunoblot	O
electrophysiology	O
rnasequencing	O
and	O
in	O
vitro	O
experiments	O
further	O
investigations	O
utilized	O
a	O
pd	B-NEURODEGENERATIVE
mouse	O
model	O
along	O
with	O
genetic	O
and	O
pharmacological	O
manipulations	O
to	O
elucidate	O
rbm24	O
involvement	O
in	O
pd	B-NEURODEGENERATIVE
pathology	O
results	O
rbm24	O
a	O
multifaceted	O
posttranscriptional	O
regulator	O
of	O
cellular	O
homeostasis	O
exhibited	O
broad	O
expression	O
in	O
the	O
svz	O
from	O
development	O
to	O
aging	O
deletion	O
of	O
rbm24	O
significantly	O
impaired	O
nspc	O
proliferation	O
in	O
the	O
adult	O
svz	O
ultimately	O
resulting	O
in	O
collapsed	O
neurogenesis	O
in	O
the	O
olfactory	O
bulb	O
notably	O
rbm24	O
played	O
a	O
specific	O
role	O
in	O
maintaining	O
notch1	O
mrna	O
stability	O
in	O
adult	O
nspcs	O
the	O
rbm24notch1	O
signaling	O
axis	O
was	O
significantly	O
downregulated	O
in	O
the	O
svz	O
of	O
pd	B-NEURODEGENERATIVE
mice	O
remarkably	O
overexpression	O
of	O
rbm24	O
rescued	O
disruption	O
of	O
adult	O
neurogenesis	O
and	O
olfactory	O
dysfunction	O
in	O
pd	B-NEURODEGENERATIVE
mice	O
and	O
these	O
effects	O
were	O
hindered	O
by	O
dapt	O
a	O
potent	O
inhibitor	O
of	O
notch1	O
conclusions	O
our	O
findings	O
highlight	O
the	O
critical	O
role	O
of	O
the	O
rbm24notch1	O
signaling	O
axis	O
in	O
regulating	O
adult	O
svz	O
neurogenesis	O
under	O
physiological	O
and	O
pathological	O
circumstances	O
this	O
provides	O
valuable	O
insights	O
into	O
the	O
dynamic	O
regulation	O
of	O
nspc	O
homeostasis	O
and	O
offers	O
a	O
potential	O
targeted	O
intervention	O
for	O
pd	B-NEURODEGENERATIVE
and	O
related	O
neurological	O
disorders	O
neuroimaging	O
biomarkers	O
and	O
impaired	O
olfaction	O
in	O
cognitively	O
normal	O
individuals	O
objective	O
there	O
is	O
a	O
need	O
for	O
inexpensive	O
noninvasive	O
tests	O
to	O
identify	O
older	O
healthy	O
persons	O
at	O
risk	O
for	O
alzheimer	B-NEURODEGENERATIVE
disease	O
ad	B-NEURODEGENERATIVE
for	O
enrollment	O
in	O
ad	B-NEURODEGENERATIVE
prevention	O
trials	O
our	O
objective	O
was	O
to	O
examine	O
whether	O
abnormalities	O
in	O
neuroimaging	O
measures	O
of	O
amyloid	O
and	O
neurodegeneration	O
are	O
correlated	O
with	O
odor	O
identification	O
oi	O
in	O
the	O
populationbased	O
mayo	O
clinic	O
study	O
of	O
aging	O
methods	O
cognitively	O
normal	O
cn	O
participants	B-PERCIEVER
had	O
olfactory	O
function	O
assessed	O
using	O
the	O
brief	O
smell	O
identification	O
test	O
bsit	B-SMELL_TEST
underwent	O
magnetic	O
resonance	O
imaging	O
n	O
829	O
to	O
assess	O
a	O
composite	O
ad	B-NEURODEGENERATIVE
signature	O
cortical	O
thickness	O
and	O
hippocampal	O
volume	O
hva	O
and	O
underwent	O
11	O
cpittsburgh	O
compound	O
b	O
n	O
306	O
and	O
18	O
fluorodeoxyglucose	O
n	O
305	O
positron	O
emission	O
tomography	O
scanning	O
to	O
assess	O
amyloid	O
accumulation	O
and	O
brain	O
hypometabolism	O
respectively	O
the	O
association	O
of	O
neuroimaging	O
biomarkers	O
with	O
oi	O
was	O
examined	O
using	O
multinomial	O
logistic	O
regression	O
and	O
simple	O
linear	O
regression	O
models	O
adjusted	O
for	O
potential	O
confounders	O
results	O
among	O
829	O
cn	O
participants	B-PERCIEVER
mean	O
age	O
792	O
years	O
515	O
men	B-PERCIEVER
248	O
299	O
were	O
normosmic	O
and	O
78	O
94	O
had	O
anosmia	B-OLFACTORY
bsit	B-SMELL_TEST
score	O
6	O
abnormal	O
ad	B-NEURODEGENERATIVE
signature	O
cortical	O
thickness	O
and	O
reduced	O
hva	O
were	O
associated	O
with	O
decreased	O
oi	O
as	O
a	O
continuous	O
measure	O
slope	O
043	O
95	O
confidence	O
interval	O
ci	O
076	O
to	O
009	O
p	O
001	O
and	O
slope	O
072	O
95	O
ci	O
115	O
to	O
028	O
p	O
001	O
respectively	O
reduced	O
hva	O
decreased	O
ad	B-NEURODEGENERATIVE
signature	O
cortical	O
thickness	O
and	O
increased	O
amyloid	O
accumulation	O
were	O
significantly	O
associated	O
with	O
increased	O
odds	O
of	O
anosmia	B-OLFACTORY
interpretation	O
our	O
findings	O
suggest	O
that	O
oi	O
may	O
be	O
a	O
noninvasive	O
inexpensive	O
marker	O
for	O
risk	O
stratification	O
for	O
identifying	O
participants	B-PERCIEVER
at	O
the	O
preclinical	O
stage	O
of	O
ad	B-NEURODEGENERATIVE
who	O
may	O
be	O
at	O
risk	O
for	O
cognitive	O
impairment	O
and	O
eligible	O
for	O
inclusion	O
in	O
ad	B-NEURODEGENERATIVE
prevention	O
clinical	O
trials	O
these	O
crosssectional	O
findings	O
remain	O
to	O
be	O
validated	O
prospectively	O
ann	O
neurol	O
201781871882	O
longitudinal	O
brain	O
changes	O
in	O
parkinsons	B-NEURODEGENERATIVE
disease	O
with	O
severe	O
olfactory	O
deficit	O
introduction	O
olfactory	O
dysfunction	O
and	O
rem	O
sleep	O
behavior	O
disorder	O
rbd	O
are	O
associated	O
with	O
distinct	O
cognitive	O
trajectories	O
in	O
the	O
course	O
of	O
parkinsons	B-NEURODEGENERATIVE
disease	O
pd	B-NEURODEGENERATIVE
the	O
underlying	O
neurobiology	O
for	O
this	O
relationship	O
remains	O
unclear	O
but	O
may	O
involve	O
distinct	O
patterns	O
of	O
neurodegeneration	O
this	O
study	O
aimed	O
to	O
examine	O
longitudinal	O
cortical	O
atrophy	O
and	O
thinning	O
in	O
earlystage	O
pd	B-NEURODEGENERATIVE
with	O
severe	O
olfactory	O
deficit	O
anosmia	B-OLFACTORY
without	O
and	O
with	O
concurrent	O
probable	O
rbd	O
methods	O
longitudinal	O
mri	O
data	O
over	O
four	O
years	O
of	O
134	O
de	O
novo	O
pd	B-NEURODEGENERATIVE
and	O
49	O
healthy	O
controls	O
hc	O
from	O
the	O
parkinson	B-NEURODEGENERATIVE
progression	O
marker	O
initiative	O
ppmi	O
cohort	O
were	O
analyzed	O
using	O
a	O
linear	O
mixedeffects	O
model	O
patients	B-PERCIEVER
were	O
categorized	O
into	O
those	O
with	O
anosmia	B-OLFACTORY
by	O
the	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O
upsit	B-SMELL_TEST
score	O
18	O
ao	O
and	O
those	O
without	O
upsit	B-SMELL_TEST
score	O
18	O
ao	O
the	O
ao	O
group	O
was	O
further	O
subdivided	O
into	O
ao	O
with	O
probable	O
rbd	O
aorbd	O
and	O
without	O
aorbd	O
for	O
subanalysis	O
results	O
compared	O
to	O
subjects	B-PERCIEVER
without	O
baseline	O
anosmia	B-OLFACTORY
the	O
ao	O
group	O
exhibited	O
greater	O
longitudinal	O
declines	O
in	O
both	O
volume	O
and	O
thickness	O
in	O
the	O
bilateral	O
parahippocampal	O
gyri	O
and	O
right	O
transverse	O
temporal	O
gyrus	O
patients	B-PERCIEVER
with	O
concurrent	O
anosmia	B-OLFACTORY
and	O
rbd	O
showed	O
more	O
extensive	O
longitudinal	O
declines	O
in	O
cortical	O
volume	O
and	O
thickness	O
involving	O
additional	O
brain	O
regions	O
including	O
the	O
bilateral	O
precuneus	O
left	O
inferior	O
temporal	O
gyrus	O
right	O
paracentral	O
gyrus	O
and	O
right	O
precentral	O
gyrus	O
conclusions	O
the	O
atrophythinning	O
patterns	O
in	O
earlystage	O
pd	B-NEURODEGENERATIVE
with	O
severe	O
olfactory	O
dysfunction	O
include	O
regions	O
that	O
are	O
critical	O
for	O
cognitive	O
function	O
and	O
could	O
provide	O
a	O
structural	O
basis	O
for	O
previously	O
reported	O
associations	O
between	O
severe	O
olfactory	O
deficit	O
and	O
cognitive	O
decline	O
in	O
pd	B-NEURODEGENERATIVE
concurrent	O
rbd	O
might	O
enhance	O
the	O
dynamics	O
of	O
cortical	O
changes	O
smell	O
and	O
preclinical	O
alzheimer	B-NEURODEGENERATIVE
disease	O
study	O
of	O
29	O
patients	B-PERCIEVER
with	O
amnesic	O
mild	O
cognitive	O
impairment	O
objectives	O
to	O
evaluate	O
the	O
olfactory	O
function	O
in	O
patients	B-PERCIEVER
with	O
amnesic	O
mild	O
cognitive	O
impairment	O
amci	O
and	O
the	O
relationship	O
to	O
the	O
progression	O
from	O
amci	O
to	O
alzheimer	B-NEURODEGENERATIVE
disease	O
ad	B-NEURODEGENERATIVE
design	O
cohort	O
prospective	O
study	O
on	O
amci	O
patients	B-PERCIEVER
at	O
the	O
first	O
evaluation	O
t0	O
and	O
at	O
the	O
18month	O
followup	O
t1	O
setting	O
alzheimer	B-NEURODEGENERATIVE
unit	O
of	O
the	O
university	O
of	O
laquila	O
italy	O
methods	O
twentynine	O
amci	O
patients	B-PERCIEVER
were	O
enrolled	O
in	O
this	O
study	O
main	O
outcome	O
measures	O
olfactory	O
function	O
was	O
studied	O
with	O
the	O
sniffin	O
sticks	O
screening	O
test	O
ssst	O
and	O
the	O
sniffin	O
sticks	O
extended	O
test	O
sset	O
olfactory	O
functions	O
were	O
related	O
to	O
neurocognitive	O
functions	O
assessed	O
by	O
the	O
minimental	O
state	O
examination	O
mmse	O
and	O
the	O
mental	O
deterioration	O
battery	O
mdb	O
results	O
at	O
t0	O
amci	O
patients	B-PERCIEVER
showed	O
an	O
olfactory	O
impairment	O
and	O
all	O
of	O
the	O
amci	O
patients	B-PERCIEVER
had	O
lower	O
olfaction	O
scores	O
at	O
t1	O
at	O
t1	O
9	O
of	O
the	O
29	O
amci	O
patients	B-PERCIEVER
31	O
developed	O
ad	B-NEURODEGENERATIVE
and	O
had	O
lower	O
mean	O
ssst	O
and	O
sset	O
scores	O
than	O
20	O
amci	O
patients	B-PERCIEVER
who	O
did	O
not	O
develop	O
ad	B-NEURODEGENERATIVE
the	O
most	O
significant	O
relationship	O
was	O
found	O
between	O
olfactory	O
discrimination	O
and	O
visuospatial	O
ability	O
language	O
skill	O
and	O
the	O
rey	O
immediate	O
test	O
of	O
the	O
mdb	O
and	O
between	O
olfactory	O
identification	O
and	O
the	O
rey	O
delayed	O
test	O
conclusion	O
odour	O
discrimination	O
and	O
identification	O
performance	O
correlated	O
more	O
prominently	O
than	O
detection	O
thresholds	O
with	O
performance	O
on	O
neuropsychological	O
tests	O
we	O
concluded	O
that	O
the	O
olfactory	O
deficit	O
occurs	O
early	O
in	O
amci	O
so	O
we	O
suggest	O
introducing	O
the	O
clinical	O
routine	O
use	O
of	O
the	O
olfactory	O
test	O
for	O
early	O
identification	O
of	O
the	O
progression	O
of	O
the	O
decline	O
from	O
amci	O
to	O
ad	B-NEURODEGENERATIVE
effects	O
of	O
caffeine	O
in	O
parkinsons	B-NEURODEGENERATIVE
disease	O
from	O
neuroprotection	O
to	O
the	O
management	O
of	O
motor	O
and	O
nonmotor	O
symptoms	O
parkinsons	B-NEURODEGENERATIVE
disease	O
pd	B-NEURODEGENERATIVE
is	O
the	O
second	O
most	O
common	O
neurodegenerative	O
disorder	O
affecting	O
approximately	O
1	O
of	O
the	O
population	O
older	O
than	O
60	O
years	O
classically	O
pd	B-NEURODEGENERATIVE
is	O
considered	O
to	O
be	O
a	O
motor	O
system	O
disease	O
and	O
its	O
diagnosis	O
is	O
based	O
on	O
the	O
presence	O
of	O
a	O
set	O
of	O
cardinal	O
motor	O
signs	O
rigidity	O
bradykinesia	O
rest	O
tremor	O
that	O
are	O
consequence	O
of	O
a	O
pronounced	O
death	O
of	O
dopaminergic	O
neurons	O
in	O
the	O
substantia	O
nigra	O
pars	O
compacta	O
nowadays	O
there	O
is	O
considerable	O
evidence	O
showing	O
that	O
nondopaminergic	O
degeneration	O
also	O
occurs	O
in	O
other	O
brain	O
areas	O
which	O
seems	O
to	O
be	O
responsible	O
for	O
the	O
deficits	O
in	O
olfactory	O
emotional	O
and	O
memory	O
functions	O
that	O
precede	O
the	O
classical	O
motor	O
symptoms	O
in	O
pd	B-NEURODEGENERATIVE
the	O
present	O
review	O
attempts	O
to	O
examine	O
results	O
reported	O
in	O
epidemiological	O
clinical	O
and	O
animal	O
studies	O
to	O
provide	O
a	O
comprehensive	O
picture	O
of	O
the	O
antiparkinsonian	O
potential	O
of	O
caffeine	O
convergent	O
epidemiological	O
and	O
preclinical	O
data	O
suggest	O
that	O
caffeine	O
may	O
confer	O
neuroprotection	O
against	O
the	O
underlying	O
dopaminergic	O
neuron	O
degeneration	O
and	O
influence	O
the	O
onset	O
and	O
progression	O
of	O
pd	B-NEURODEGENERATIVE
the	O
available	O
data	O
also	O
suggest	O
that	O
caffeine	O
can	O
improve	O
the	O
motor	O
deficits	O
of	O
pd	B-NEURODEGENERATIVE
and	O
that	O
adenosine	O
a2a	O
receptor	O
antagonists	O
such	O
as	O
istradefylline	O
reduces	O
off	O
time	O
and	O
dyskinesia	O
associated	O
with	O
standard	O
dopamine	O
replacement	O
treatments	O
finally	O
recent	O
experimental	O
findings	O
have	O
indicated	O
the	O
potential	O
of	O
caffeine	O
in	O
the	O
management	O
of	O
nonmotor	O
symptoms	O
of	O
pd	B-NEURODEGENERATIVE
which	O
do	O
not	O
improve	O
with	O
the	O
current	O
dopaminergic	O
drugs	O
altogether	O
the	O
studies	O
reviewed	O
provide	O
strong	O
evidence	O
that	O
caffeine	O
may	O
represent	O
a	O
promising	O
therapeutic	O
tool	O
in	O
pd	B-NEURODEGENERATIVE
thus	O
being	O
the	O
first	O
compound	O
to	O
restore	O
both	O
motor	O
and	O
nonmotor	O
early	O
symptoms	O
of	O
pd	B-NEURODEGENERATIVE
together	O
with	O
its	O
neuroprotective	O
potential	O
anosmia	B-OLFACTORY
mild	O
cognitive	O
impairment	O
and	O
biomarkers	O
of	O
brain	O
aging	O
in	O
older	O
adults	O
olfactory	O
impairment	O
is	O
a	O
potential	O
marker	O
for	O
prodromal	O
dementia	B-NEURODEGENERATIVE
but	O
the	O
underlying	O
mechanisms	O
are	O
poorly	O
understood	O
this	O
populationbased	O
study	O
included	O
4214	O
dementiafree	O
participants	B-PERCIEVER
age	O
65	O
years	O
olfaction	O
was	O
assessed	O
using	O
the	O
16item	O
sniffin	O
sticks	O
identification	O
test	O
in	O
the	O
subsamples	O
we	O
measured	O
plasma	O
amyloid	O
beta	O
abeta40	O
abeta42	O
total	O
tau	O
and	O
neurofilament	O
light	O
chain	O
nfl	O
n	O
1054	O
and	O
quantified	O
hippocampal	O
entorhinal	O
cortex	O
and	O
white	O
matter	O
hyperintensity	O
wmh	O
volumes	O
and	O
alzheimers	B-NEURODEGENERATIVE
disease	O
adsignature	O
cortical	O
thickness	O
n	O
917	O
data	O
were	O
analyzed	O
with	O
logistic	O
and	O
linear	O
regression	O
models	O
in	O
the	O
total	O
sample	O
mild	O
cognitive	O
impairment	O
mci	O
was	O
diagnosed	O
in	O
1102	O
persons	O
262	O
amnestic	O
mci	O
n	O
931	O
nonamnestic	O
mci	O
n	O
171	O
olfactory	O
impairment	O
was	O
significantly	O
associated	O
with	O
increased	O
likelihoods	O
of	O
mci	O
amnestic	O
mci	O
and	O
nonamnestic	O
mci	O
in	O
the	O
subsamples	O
anosmia	B-OLFACTORY
was	O
significantly	O
associated	O
with	O
higher	O
plasma	O
total	O
tau	O
and	O
nfl	O
concentrations	O
smaller	O
hippocampal	O
and	O
entorhinal	O
cortex	O
volumes	O
and	O
greater	O
wmh	O
volume	O
and	O
marginally	O
with	O
lower	O
adsignature	O
cortical	O
thickness	O
these	O
results	O
suggest	O
that	O
cerebral	O
neurodegenerative	O
and	O
microvascular	O
lesions	O
are	O
common	O
neuropathologies	O
linking	O
anosmia	B-OLFACTORY
with	O
mci	O
in	O
older	O
adults	O
orthonasal	O
but	O
not	O
retronasal	O
olfaction	O
is	O
specifically	O
impaired	O
in	O
parkinsons	B-NEURODEGENERATIVE
disease	O
olfactory	O
dysfunction	O
od	O
in	O
parkinsons	B-NEURODEGENERATIVE
disease	O
pd	B-NEURODEGENERATIVE
appears	O
several	O
years	O
before	O
the	O
presence	O
of	O
motor	O
disturbance	O
olfactory	O
testing	O
has	O
the	O
potential	O
to	O
serve	O
as	O
a	O
tool	O
for	O
early	O
detection	O
of	O
pd	B-NEURODEGENERATIVE
but	O
od	O
is	O
not	O
specific	O
to	O
pd	B-NEURODEGENERATIVE
as	O
it	O
affects	O
up	O
to	O
20	O
of	O
the	O
general	O
population	O
olfaction	O
includes	O
an	O
orthonasal	O
and	O
a	O
retronasal	O
components	O
in	O
some	O
forms	O
of	O
od	O
retronasal	O
olfactory	O
function	O
is	O
preserved	O
we	O
aimed	O
to	O
evaluate	O
whether	O
combined	O
testing	O
components	O
allows	O
for	O
discriminating	O
between	O
pdrelated	O
od	O
and	O
nonparkinsonian	O
od	O
npod	O
the	O
objective	O
of	O
this	O
study	O
is	O
to	O
orthonasal	O
and	O
retronasal	O
olfactory	O
function	O
in	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
and	O
compare	O
them	O
to	O
a	O
npod	O
group	O
and	O
to	O
healthy	O
controls	O
we	O
hypothesized	O
that	O
this	O
combined	O
testing	O
allows	O
to	O
distinguish	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
from	O
both	O
other	O
groups	O
we	O
included	O
32	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
25	O
npod	O
patients	B-PERCIEVER
and	O
15	O
healthy	O
controls	O
both	O
olfactory	O
components	O
were	O
impaired	O
in	O
pd	B-NEURODEGENERATIVE
and	O
npod	O
patients	B-PERCIEVER
compared	O
with	O
controls	O
however	O
npod	O
patients	B-PERCIEVER
had	O
significantly	O
better	O
orthonasal	O
scores	O
than	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
furthermore	O
the	O
ratio	O
of	O
retronasalorthonasal	O
score	O
was	O
higher	O
in	O
pd	B-NEURODEGENERATIVE
than	O
in	O
both	O
other	O
groups	O
in	O
the	O
npod	O
group	O
orthonasal	O
and	O
retronasal	O
scores	O
were	O
significantly	O
correlated	O
no	O
such	O
correlation	O
could	O
be	O
observed	O
in	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
in	O
summary	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
seem	O
to	O
rely	O
on	O
compensatory	O
mechanisms	O
for	O
flavor	O
perception	O
combined	O
orthonasal	O
and	O
retronasal	O
olfactory	O
testing	O
may	O
contribute	O
to	O
differentiate	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
from	O
patients	B-PERCIEVER
with	O
npod	O
inability	O
to	O
smell	O
peppermint	B-SMELL_SOURCE
is	O
related	O
to	O
cognitive	O
decline	O
a	O
prospective	O
communitybased	O
study	O
background	O
a	O
few	O
studies	O
have	O
demonstrated	O
the	O
association	O
of	O
poorer	O
olfactory	O
identification	O
oi	O
with	O
poorer	O
cognition	O
in	O
populationbased	O
cohorts	O
none	O
of	O
them	O
considered	O
the	O
outcome	O
associated	O
with	O
the	O
inability	O
to	O
smell	O
a	O
certain	O
odor	O
objective	O
to	O
verify	O
the	O
hypothesis	O
that	O
at	O
least	O
one	O
specific	O
odor	O
is	O
associated	O
with	O
incident	O
cognitive	O
decline	O
among	O
older	O
adults	O
methods	O
in	O
the	O
shanghai	O
aging	O
study	O
a	O
subcohort	O
of	O
948	O
dementiafree	O
participants	B-PERCIEVER
who	O
had	O
baseline	O
oi	O
measurements	O
were	O
prospectively	O
followed	O
for	O
5	O
years	O
results	O
an	O
inability	O
to	O
smell	O
peppermint	B-SMELL_SOURCE
beta	O
044	O
p	O
0001	O
rose	O
beta	O
014	O
p	O
0040	O
or	O
coffee	O
beta	O
037	O
p	O
0002	O
was	O
inversely	O
related	O
to	O
the	O
annual	O
rate	O
of	O
change	O
in	O
the	O
mini	O
mental	O
state	O
examination	O
score	O
and	O
an	O
inability	O
to	O
smell	O
peppermint	B-SMELL_SOURCE
was	O
associated	O
with	O
a	O
higher	O
risk	O
for	O
incident	O
dementia	B-NEURODEGENERATIVE
hazard	O
ratio	O
267	O
95	O
ci	O
144496	O
after	O
adjustment	O
for	O
confounders	O
conclusion	O
our	O
study	O
suggests	O
that	O
some	O
odors	O
especially	O
peppermint	B-SMELL_SOURCE
might	O
be	O
considered	O
as	O
a	O
potential	O
predictor	O
for	O
dementia	B-NEURODEGENERATIVE
in	O
older	O
populations	O
phantosmias	O
and	O
parkinson	B-NEURODEGENERATIVE
disease	O
background	O
impaired	O
olfaction	O
is	O
a	O
common	O
nonmotor	O
manifestation	O
of	O
parkinson	B-NEURODEGENERATIVE
disease	O
pd	B-NEURODEGENERATIVE
however	O
to	O
our	O
knowledge	O
qualitative	O
olfactory	O
disturbances	O
such	O
as	O
odor	O
distortions	O
have	O
not	O
been	O
extensively	O
reported	O
in	O
this	O
condition	O
objective	O
to	O
describe	O
2	O
patients	B-PERCIEVER
who	O
reported	O
positive	O
olfactory	O
symptoms	O
preceding	O
typical	O
pd	B-NEURODEGENERATIVE
which	O
were	O
consistent	O
with	O
olfactory	O
hallucinations	O
phantosmias	O
in	O
the	O
absence	O
of	O
major	O
smell	O
deficit	O
design	O
case	O
series	O
setting	O
university	O
hospital	O
patients	B-PERCIEVER
we	O
describe	O
2	O
patients	B-PERCIEVER
both	O
seen	O
in	O
2007	O
who	O
reported	O
pleasant	O
olfactory	O
hallucinations	O
for	O
several	O
years	O
main	O
outcome	O
measures	O
iodine	O
i	O
123labeled	O
ioflupane	O
singlephoton	O
emission	O
computed	O
tomography	O
and	O
olfactometric	O
testing	O
results	O
results	O
the	O
123ilabeled	O
ioflupane	O
singlephoton	O
emission	O
computed	O
tomography	O
showed	O
reduced	O
radiotracer	O
uptake	O
in	O
both	O
striatum	O
more	O
marked	O
in	O
the	O
putamen	O
and	O
on	O
the	O
left	O
side	O
in	O
patient	B-PERCIEVER
1	O
and	O
reduced	O
radiotracer	O
uptake	O
in	O
both	O
putamen	O
more	O
marked	O
on	O
the	O
right	O
side	O
in	O
patient	B-PERCIEVER
2	O
olfactometric	O
testing	O
showed	O
mild	O
hyposmia	B-OLFACTORY
in	O
patient	B-PERCIEVER
1	O
and	O
normal	O
function	O
in	O
patient	B-PERCIEVER
2	O
the	O
disappearance	O
of	O
the	O
phantosmias	O
in	O
both	O
patients	B-PERCIEVER
coincided	O
with	O
the	O
development	O
of	O
typical	O
pd	B-NEURODEGENERATIVE
conclusion	O
we	O
propose	O
phantosmia	B-OLFACTORY
as	O
a	O
new	O
premotor	O
manifestation	O
of	O
pd	B-NEURODEGENERATIVE
and	O
suggest	O
that	O
qualitative	O
abnormalities	O
of	O
olfaction	O
rather	O
than	O
the	O
typical	O
smell	O
loss	O
demonstrated	O
in	O
this	O
condition	O
should	O
be	O
more	O
carefully	O
examined	O
in	O
the	O
prodromal	O
phase	O
of	O
pd	B-NEURODEGENERATIVE
seedinduced	O
abeta	O
deposition	O
alters	O
neuronal	O
function	O
and	O
impairs	O
olfaction	O
in	O
a	O
mouse	O
model	O
of	O
alzheimers	B-NEURODEGENERATIVE
disease	O
alzheimers	B-NEURODEGENERATIVE
disease	O
ad	B-NEURODEGENERATIVE
is	O
characterized	O
by	O
the	O
accumulation	O
of	O
amyloidbeta	O
abeta	O
which	O
ultimately	O
forms	O
plaques	O
these	O
abeta	O
deposits	O
can	O
be	O
induced	O
in	O
app	O
transgenic	O
mouse	O
models	O
by	O
prionlike	O
seeding	O
it	O
has	O
been	O
widely	O
accepted	O
that	O
anosmia	B-OLFACTORY
and	O
hyposmia	B-OLFACTORY
occur	O
during	O
the	O
early	O
stages	O
of	O
ad	B-NEURODEGENERATIVE
even	O
before	O
cognitive	O
deficits	O
are	O
present	O
in	O
order	O
to	O
determine	O
the	O
impact	O
of	O
seedinduced	O
abeta	O
deposits	O
on	O
olfaction	O
we	O
performed	O
intracerebral	O
injections	O
of	O
seedcompetent	O
brain	O
homogenate	O
into	O
the	O
olfactory	O
bulb	O
of	O
young	O
predepositing	O
app	O
transgenic	O
mice	O
remarkably	O
we	O
observed	O
a	O
dramatic	O
olfactory	O
impairment	O
in	O
those	O
mice	O
furthermore	O
the	O
number	O
of	O
newborn	O
neurons	O
as	O
well	O
as	O
the	O
activity	O
of	O
cells	O
in	O
the	O
mitral	O
cell	O
layer	O
was	O
decreased	O
notably	O
exposure	O
to	O
an	O
enriched	O
environment	O
reduced	O
abeta	O
seeding	O
vivified	O
neurogenesis	O
and	O
most	O
importantly	O
reversed	O
olfactory	O
deficits	O
based	O
on	O
our	O
findings	O
we	O
conclude	O
that	O
altered	O
neuronal	O
function	O
as	O
a	O
result	O
of	O
induced	O
abeta	O
pathology	O
might	O
contribute	O
to	O
olfactory	O
dysfunction	O
in	O
ad	B-NEURODEGENERATIVE
anosmia	B-OLFACTORY
in	O
dementia	B-NEURODEGENERATIVE
is	O
associated	O
with	O
lewy	O
bodies	O
rather	O
than	O
alzheimers	B-NEURODEGENERATIVE
pathology	O
objectives	O
to	O
assess	O
olfactory	O
function	O
of	O
patients	B-PERCIEVER
with	O
dementia	B-NEURODEGENERATIVE
odour	O
detection	O
ability	O
is	O
impaired	O
in	O
clinical	O
parkinsons	B-NEURODEGENERATIVE
disease	O
evidence	O
of	O
impaired	O
detection	O
in	O
patients	B-PERCIEVER
with	O
clinically	O
diagnosed	O
alzheimers	B-NEURODEGENERATIVE
disease	O
is	O
inconsistent	O
no	O
studies	O
of	O
olfaction	O
have	O
been	O
neuropathologically	O
validated	O
methods	O
the	O
olfactory	O
function	O
of	O
92	O
patients	B-PERCIEVER
with	O
dementia	B-NEURODEGENERATIVE
and	O
94	O
controls	O
was	O
assessed	O
using	O
a	O
simple	O
bedside	O
test	O
as	O
part	O
of	O
the	O
oxford	O
project	O
to	O
investigate	O
memory	O
and	O
ageing	O
optima	O
neuropathological	O
assessment	O
was	O
made	O
of	O
cortical	O
lewy	O
bodies	O
and	O
substantia	O
nigra	O
sn	O
cell	O
counts	O
and	O
of	O
alzheimers	B-NEURODEGENERATIVE
disease	O
in	O
all	O
92	O
patients	B-PERCIEVER
22	O
of	O
whom	O
had	O
sn	O
lewy	O
bodies	O
and	O
43	O
of	O
whom	O
had	O
only	O
alzheimers	B-NEURODEGENERATIVE
disease	O
results	O
patients	B-PERCIEVER
with	O
lewy	O
bodies	O
were	O
more	O
likely	O
to	O
be	O
anosmic	O
than	O
those	O
with	O
alzheimers	B-NEURODEGENERATIVE
disease	O
or	O
controls	O
patients	B-PERCIEVER
with	O
alzheimers	B-NEURODEGENERATIVE
disease	O
were	O
not	O
more	O
likely	O
to	O
be	O
anosmic	O
than	O
controls	O
nor	O
was	O
anosmia	B-OLFACTORY
associated	O
with	O
degree	O
of	O
neurofibrillary	O
tangles	O
as	O
assessed	O
by	O
braak	O
stage	O
among	O
subjects	B-PERCIEVER
with	O
lewy	O
bodies	O
overall	O
cortical	O
lewy	O
body	O
scores	O
and	O
lewy	O
body	O
density	O
in	O
the	O
cingulate	O
were	O
higher	O
in	O
those	O
who	O
were	O
anosmic	O
consensus	O
clinical	O
criteria	O
for	O
dementia	B-NEURODEGENERATIVE
with	O
lewy	O
bodies	O
had	O
a	O
sensitivity	O
of	O
64	O
and	O
specificity	O
of	O
89	O
in	O
the	O
absence	O
of	O
definite	O
alzheimers	B-NEURODEGENERATIVE
disease	O
the	O
criteria	O
had	O
sensitivity	O
of	O
100	O
in	O
patients	B-PERCIEVER
with	O
definite	O
alzheimers	B-NEURODEGENERATIVE
disease	O
anosmia	B-OLFACTORY
was	O
slightly	O
more	O
sensitive	O
55	O
than	O
the	O
consensus	O
criteria	O
33	O
however	O
the	O
addition	O
of	O
anosmia	B-OLFACTORY
to	O
the	O
consensus	O
criteria	O
did	O
not	O
improve	O
their	O
overall	O
performance	O
conclusion	O
dementia	B-NEURODEGENERATIVE
with	O
lewy	O
bodies	O
is	O
associated	O
with	O
impaired	O
odour	O
detection	O
misdiagnosis	O
may	O
have	O
accounted	O
for	O
some	O
previous	O
reports	O
of	O
impaired	O
odour	O
detection	O
in	O
alzheimers	B-NEURODEGENERATIVE
disease	O
simple	O
but	O
more	O
sensitive	O
tests	O
of	O
anosmia	B-OLFACTORY
are	O
required	O
if	O
they	O
are	O
to	O
be	O
clinically	O
useful	O
in	O
identifying	O
patients	B-PERCIEVER
with	O
dementia	B-NEURODEGENERATIVE
with	O
lewy	O
bodies	O
alphasynuclein	O
pathology	O
in	O
the	O
olfactory	O
pathways	O
of	O
dementia	B-NEURODEGENERATIVE
patients	B-PERCIEVER
lewytype	O
pathology	O
is	O
a	O
characteristic	O
of	O
a	O
number	O
of	O
neurodegenerative	O
disorders	O
including	O
parkinsons	B-NEURODEGENERATIVE
disease	O
and	O
dementia	B-NEURODEGENERATIVE
with	O
lewy	O
bodies	O
thus	O
far	O
the	O
definitive	O
diagnosis	O
of	O
these	O
dementias	O
can	O
only	O
be	O
confirmed	O
at	O
postmortem	O
however	O
it	O
is	O
known	O
that	O
the	O
loss	O
of	O
smell	O
anosmia	B-OLFACTORY
is	O
an	O
early	O
symptom	O
in	O
patients	B-PERCIEVER
who	O
develop	O
dementia	B-NEURODEGENERATIVE
and	O
the	O
use	O
of	O
the	O
smell	O
test	O
has	O
been	O
proposed	O
as	O
an	O
early	O
diagnostic	O
procedure	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
understand	O
further	O
the	O
extent	O
of	O
lewy	O
pathology	O
in	O
the	O
olfactory	O
system	O
of	O
patients	B-PERCIEVER
with	O
neurodegenerative	O
disorders	O
postmortem	O
tissue	O
from	O
250	O
subjects	B-PERCIEVER
was	O
obtained	O
from	O
the	O
optima	O
brain	O
bank	O
five	O
areas	O
of	O
the	O
olfactory	O
pathway	O
were	O
examined	O
by	O
immunolabelling	O
for	O
alphasynuclein	O
a	O
major	O
component	O
of	O
lewy	O
pathology	O
the	O
olfactory	O
tractbulb	O
n	O
79	O
the	O
anterior	O
olfactory	O
nucleus	O
in	O
the	O
lateral	O
olfactory	O
gyrus	O
n	O
193	O
the	O
region	O
of	O
olfactory	O
projection	O
to	O
the	O
orbitofrontal	O
cortex	O
n	O
225	O
the	O
hippocampus	O
n	O
236	O
and	O
the	O
amygdala	O
n	O
201	O
results	O
show	O
that	O
lewy	O
pathology	O
affects	O
different	O
parts	O
of	O
the	O
olfactory	O
pathways	O
differentially	O
suggesting	O
a	O
specific	O
pattern	O
of	O
development	O
of	O
pathology	O
clinical	O
parkinsons	B-NEURODEGENERATIVE
disease	O
is	O
most	O
likely	O
to	O
be	O
identified	O
if	O
the	O
orbitofrontal	O
cortex	O
is	O
affected	O
while	O
the	O
diagnosis	O
is	O
less	O
likely	O
if	O
the	O
pathology	O
is	O
restricted	O
to	O
the	O
olfactory	O
bulb	O
or	O
tract	O
these	O
results	O
suggest	O
that	O
pathology	O
in	O
the	O
olfactory	O
bulb	O
and	O
tract	O
occurs	O
prior	O
to	O
clinical	O
signs	O
of	O
parkinsons	B-NEURODEGENERATIVE
disease	O
furthermore	O
the	O
results	O
presented	O
here	O
provide	O
further	O
evidence	O
supporting	O
the	O
possible	O
value	O
of	O
a	O
smell	O
test	O
to	O
aid	O
the	O
clinical	O
diagnosis	O
of	O
neurodegenerative	O
diseases	O
olfaction	O
deterioration	O
in	O
cognitive	O
disorders	O
in	O
the	O
elderly	O
background	O
parkinsons	B-NEURODEGENERATIVE
and	O
alzheimers	B-NEURODEGENERATIVE
diseases	O
are	O
widespread	O
neurodegenerative	O
pathologies	O
parkinsons	B-NEURODEGENERATIVE
disease	O
affects	O
about	O
1	O
of	O
the	O
population	O
over	O
the	O
age	O
of	O
65	O
years	O
while	O
alzheimer	B-NEURODEGENERATIVE
is	O
considered	O
the	O
most	O
common	O
cause	O
of	O
dementia	B-NEURODEGENERATIVE
with	O
an	O
annual	O
incidence	O
of	O
1	O
in	O
persons	O
aged	O
65	O
years	O
it	O
has	O
been	O
demonstrated	O
that	O
both	O
these	O
neurodegenerative	O
diseases	O
are	O
associated	O
with	O
smell	O
dysfunction	O
aim	O
the	O
aim	O
of	O
the	O
present	O
review	O
is	O
to	O
describe	O
briefly	O
modern	O
olfactory	O
evaluation	O
tools	O
as	O
well	O
as	O
the	O
importance	O
of	O
olfactory	O
sensitivity	O
screening	O
in	O
the	O
elderly	O
especially	O
where	O
cognitive	O
disorders	O
such	O
as	O
alzheimers	B-NEURODEGENERATIVE
or	O
parkinsons	B-NEURODEGENERATIVE
diseases	O
are	O
suspected	O
methods	O
a	O
brief	O
literature	O
review	O
focusing	O
on	O
the	O
basic	O
principle	O
of	O
smell	O
tests	O
is	O
illustrated	O
together	O
with	O
their	O
application	O
in	O
elderly	O
patients	B-PERCIEVER
affected	O
by	O
cognitive	O
disorders	O
in	O
particular	O
parkinsons	B-NEURODEGENERATIVE
and	O
alzheimers	B-NEURODEGENERATIVE
diseases	O
resultsconclusions	O
alzheimers	B-NEURODEGENERATIVE
and	O
parkinsons	B-NEURODEGENERATIVE
diseases	O
are	O
both	O
neurodegenerative	O
disorders	O
typically	O
found	O
in	O
the	O
elderly	O
as	O
both	O
diseases	O
are	O
characterized	O
by	O
the	O
early	O
presence	O
of	O
dysosmia	O
simple	O
validated	O
smell	O
tests	O
could	O
very	O
well	O
help	O
clinicians	O
in	O
the	O
early	O
diagnosis	O
of	O
these	O
neuropathological	O
conditions	O
elderly	O
patients	B-PERCIEVER
complaining	O
of	O
smell	O
loss	O
and	O
found	O
to	O
be	O
dysosmic	O
by	O
means	O
of	O
validated	O
olfactory	O
tests	O
should	O
be	O
neurologically	O
evaluated	O
as	O
early	O
as	O
possible	O
to	O
detect	O
slight	O
motor	O
abnormalities	O
in	O
an	O
atrisk	O
population	O
sudden	O
intrabulbar	O
amyloid	O
increase	O
simultaneously	O
disrupts	O
olfactory	O
bulb	O
oscillations	O
and	O
odor	O
detection	O
there	O
seems	O
to	O
be	O
a	O
correlation	O
between	O
soluble	O
amyloid	O
beta	O
protein	O
abeta	O
accumulation	O
in	O
the	O
main	O
olfactory	O
bulb	O
ob	O
and	O
smell	O
deterioration	O
in	O
both	O
alzheimers	B-NEURODEGENERATIVE
disease	O
ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER
and	O
animal	O
models	O
moreover	O
this	O
loss	O
of	O
smell	O
appears	O
to	O
be	O
related	O
to	O
alterations	O
in	O
neural	O
network	O
activity	O
in	O
several	O
olfactoryrelated	O
circuits	O
including	O
the	O
ob	O
as	O
has	O
been	O
observed	O
in	O
anesthetized	O
animals	O
and	O
brain	O
slices	O
it	O
is	O
possible	O
that	O
there	O
is	O
a	O
correlation	O
between	O
these	O
two	O
pathological	O
phenomena	O
but	O
a	O
direct	O
and	O
simultaneous	O
evaluation	O
of	O
the	O
acute	O
and	O
direct	O
effect	O
of	O
abeta	O
on	O
ob	O
activity	O
while	O
animals	O
are	O
actually	O
smelling	O
has	O
not	O
been	O
performed	O
thus	O
here	O
we	O
tested	O
the	O
effects	O
of	O
acute	O
intrabulbar	O
injection	O
of	O
abeta	O
at	O
a	O
low	O
dose	O
200	O
pmol	O
on	O
the	O
ob	O
local	O
field	O
potential	O
before	O
and	O
during	O
the	O
presence	O
of	O
a	O
hidden	O
piece	O
of	O
smelly	O
food	O
our	O
results	O
show	O
that	O
abeta	O
decreases	O
the	O
power	O
of	O
ob	O
network	O
activity	O
while	O
impairing	O
the	O
animals	O
ability	O
to	O
reach	O
the	O
hidden	O
food	O
we	O
found	O
a	O
strong	O
relationship	O
between	O
the	O
power	O
of	O
the	O
ob	O
oscillations	O
and	O
the	O
correlation	O
between	O
obs	O
and	O
the	O
olfactory	O
detection	O
test	O
scores	O
these	O
findings	O
provide	O
a	O
direct	O
link	O
between	O
abetainduced	O
ob	O
network	O
dysfunction	O
and	O
smell	O
loss	O
in	O
rodents	O
which	O
could	O
be	O
extrapolated	O
to	O
ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER
olfaction	O
and	O
dementia	B-NEURODEGENERATIVE
preliminary	O
results	O
of	O
a	O
clinical	O
and	O
experimental	O
study	O
with	O
npropanol	O
various	O
reports	O
concerning	O
the	O
oroalimentary	O
ducts	O
of	O
dements	O
and	O
increasing	O
arguments	O
in	O
favour	O
of	O
a	O
new	O
etiopathogenic	O
hypothesis	O
for	O
picks	O
disease	O
involving	O
impaired	O
zinc	O
metabolism	O
and	O
histological	O
lesions	O
partly	O
linked	O
with	O
the	O
hodology	O
of	O
the	O
olfactory	O
system	O
lie	O
at	O
the	O
origin	O
of	O
our	O
present	O
clinical	O
interest	O
in	O
olfaction	O
in	O
a	O
first	O
stage	O
using	O
a	O
technique	O
based	O
on	O
dilution	O
with	O
npropanol	O
we	O
observed	O
certain	O
conditions	O
permitting	O
an	O
evaluation	O
of	O
the	O
olfactory	O
capacities	O
of	O
patients	B-PERCIEVER
with	O
picks	O
disease	O
senile	O
plaque	O
dementia	B-NEURODEGENERATIVE
and	O
neurofibrillary	O
degenerescense	O
there	O
does	O
not	O
seem	O
to	O
be	O
a	O
decline	O
in	O
olfaction	O
with	O
age	O
olfactory	O
capacities	O
in	O
the	O
two	O
forms	O
of	O
dementia	B-NEURODEGENERATIVE
studied	O
were	O
distinctly	O
inferior	O
to	O
those	O
of	O
nondements	O
olfactory	O
habituation	O
was	O
more	O
marked	O
especially	O
in	O
picks	O
disease	O
where	O
there	O
were	O
also	O
paradoxical	O
responses	O
which	O
seemed	O
to	O
form	O
part	O
of	O
a	O
more	O
general	O
change	O
in	O
reaction	O
to	O
stimulus	O
in	O
senile	O
plaque	O
dementia	B-NEURODEGENERATIVE
and	O
neurofibrillary	O
degenerescence	O
the	O
response	O
to	O
olfactory	O
stimulus	O
declines	O
with	O
dilution	O
of	O
npropanol	O
and	O
lesional	O
extension	O
observation	O
of	O
recorded	O
parameters	O
eeg	O
psychogalvanic	O
reflex	O
ocular	O
movement	O
breathing	O
is	O
useful	O
in	O
picks	O
disease	O
and	O
may	O
be	O
difficult	O
in	O
senile	O
plaque	O
dementia	B-NEURODEGENERATIVE
and	O
neurofibrillary	O
degenerescence	O
olfactory	O
capacities	O
appear	O
to	O
constitute	O
an	O
additional	O
criterion	O
on	O
which	O
to	O
base	O
a	O
diagnosis	O
of	O
dementia	B-NEURODEGENERATIVE
they	O
could	O
be	O
used	O
to	O
help	O
establish	O
the	O
neurobiological	O
bases	O
of	O
certain	O
types	O
of	O
demential	O
behaviour	O
and	O
to	O
observe	O
the	O
progress	O
of	O
tentative	O
therapies	O
olfactory	O
cortex	O
degeneration	O
in	O
alzheimers	B-NEURODEGENERATIVE
disease	O
and	O
mild	O
cognitive	O
impairment	O
background	O
olfactory	O
deficits	O
are	O
prevalent	O
in	O
patients	B-PERCIEVER
with	O
alzheimers	B-NEURODEGENERATIVE
disease	O
ad	B-NEURODEGENERATIVE
and	O
mild	O
cognitive	O
impairment	O
mci	O
these	O
symptoms	O
precede	O
clinical	O
onset	O
of	O
cognitive	O
and	O
memory	O
deficits	O
and	O
coincide	O
with	O
ad	B-NEURODEGENERATIVE
pathology	O
preferentially	O
in	O
the	O
central	O
olfactory	O
structures	O
suggesting	O
a	O
potential	O
biomarker	O
for	O
ad	B-NEURODEGENERATIVE
early	O
detection	O
and	O
progression	O
objective	O
therefore	O
we	O
tested	O
the	O
hypothesis	O
that	O
structural	O
degeneration	O
of	O
the	O
primary	O
olfactory	O
cortex	O
poc	O
could	O
be	O
detected	O
in	O
ad	B-NEURODEGENERATIVE
as	O
well	O
as	O
in	O
mci	O
patients	B-PERCIEVER
and	O
would	O
be	O
correlated	O
with	O
olfactory	O
functional	O
magnetic	O
resonance	O
imaging	O
fmri	O
alterations	O
reflecting	O
loss	O
of	O
olfactory	O
cortex	O
activity	O
methods	O
total	O
structural	O
volumes	O
and	O
fmri	O
activation	O
volumes	O
of	O
the	O
poc	O
and	O
hippocampus	O
were	O
measured	O
along	O
with	O
olfactory	O
and	O
cognitive	O
behavioral	O
tests	O
in	O
27	O
cognitively	O
normal	O
cn	O
21	O
mci	O
and	O
15	O
ad	B-NEURODEGENERATIVE
subjects	B-PERCIEVER
results	O
prominent	O
atrophy	O
in	O
the	O
poc	O
and	O
hippocampus	O
was	O
found	O
in	O
both	O
ad	B-NEURODEGENERATIVE
and	O
mci	O
subjects	B-PERCIEVER
and	O
correlated	O
with	O
behavioral	O
measurements	O
while	O
behavioral	O
and	O
volumetric	O
measurements	O
showed	O
a	O
gradual	O
decline	O
from	O
cn	O
to	O
mci	O
to	O
ad	B-NEURODEGENERATIVE
olfactory	O
activation	O
volume	O
in	O
the	O
poc	O
and	O
hippocampus	O
showed	O
a	O
steeper	O
decline	O
in	O
the	O
mci	O
group	O
compared	O
to	O
corresponding	O
tissue	O
volume	O
resembling	O
the	O
ad	B-NEURODEGENERATIVE
group	O
conclusions	O
decline	O
in	O
olfactory	O
activity	O
was	O
correlated	O
with	O
the	O
ad	B-NEURODEGENERATIVE
structural	O
degeneration	O
in	O
the	O
poc	O
a	O
more	O
prominent	O
olfactory	O
activity	O
deficit	O
than	O
that	O
of	O
behavioral	O
and	O
tissue	O
volume	O
measurements	O
was	O
shown	O
in	O
the	O
mci	O
stage	O
olfactory	O
fmri	O
may	O
thus	O
provide	O
an	O
earlier	O
and	O
more	O
sensitive	O
measure	O
of	O
functional	O
neurodegeneration	O
in	O
ad	B-NEURODEGENERATIVE
and	O
mci	O
patients	B-PERCIEVER
exploring	O
white	O
matter	O
microstructure	O
and	O
olfaction	O
dysfunction	O
in	O
early	O
parkinson	B-NEURODEGENERATIVE
disease	O
diffusion	O
mri	O
reveals	O
new	O
insight	O
olfaction	O
dysfunction	O
is	O
considered	O
as	O
a	O
robust	O
marker	O
of	O
prodromal	O
parkinson	B-NEURODEGENERATIVE
disease	O
pd	B-NEURODEGENERATIVE
measurement	O
of	O
olfaction	O
function	O
as	O
a	O
screening	O
test	O
is	O
unsatisfactory	O
due	O
to	O
long	O
lead	O
time	O
interval	O
and	O
low	O
specificity	O
for	O
detection	O
of	O
pd	B-NEURODEGENERATIVE
use	O
of	O
imaging	O
markers	O
might	O
yield	O
more	O
accurate	O
predictive	O
values	O
and	O
provide	O
bases	O
for	O
combined	O
use	O
of	O
imaging	O
and	O
clinical	O
markers	O
for	O
early	O
pd	B-NEURODEGENERATIVE
diffusion	O
mri	O
connectometry	O
was	O
conducted	O
on	O
85	O
de	O
novo	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
in	O
and	O
36	O
healthy	O
controls	O
to	O
find	O
first	O
white	O
matter	O
tracts	O
with	O
significant	O
difference	O
in	O
quantitative	O
anisotropy	O
between	O
pd	B-NEURODEGENERATIVE
groups	O
with	O
various	O
degrees	O
of	O
olfaction	O
dysfunction	O
and	O
second	O
second	O
fibers	O
with	O
correlation	O
with	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O
upsit	B-SMELL_TEST
score	O
in	O
each	O
group	O
using	O
a	O
multiple	O
regression	O
analysis	O
considering	O
age	O
sex	O
gds	O
and	O
moca	O
score	O
local	O
connectomes	O
were	O
determined	O
in	O
seven	O
of	O
all	O
the	O
possible	O
comparisons	O
correcting	O
for	O
false	O
discovery	O
rate	O
fdr	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
with	O
anosmia	B-OLFACTORY
and	O
normal	O
olfaction	O
had	O
the	O
highest	O
number	O
of	O
fibers	O
with	O
decreased	O
connectivity	O
in	O
left	O
inferior	O
longitudinal	O
fasciculus	O
bilateral	O
fornix	O
bilateral	O
middle	O
cerebellar	O
peduncle	O
mcp	O
bilateral	O
cingulum	O
bilateral	O
corticospinal	O
tract	O
cst	O
and	O
body	O
genu	O
and	O
splenium	O
of	O
corpus	O
callosum	O
cc	O
fdr	O
00013	O
in	O
multiple	O
regression	O
analysis	O
connectivity	O
in	O
the	O
body	O
genu	O
and	O
splenium	O
of	O
cc	O
and	O
bilateral	O
fornix	O
had	O
significant	O
negative	O
correlation	O
fdr	O
between	O
0019	O
and	O
0083	O
and	O
bilateral	O
cingulum	O
and	O
mcp	O
had	O
significant	O
positive	O
correlation	O
fdr	O
between	O
0022	O
and	O
0092	O
with	O
upsit	B-SMELL_TEST
score	O
white	O
matter	O
connectivity	O
in	O
healthy	O
controls	O
could	O
not	O
be	O
predicted	O
by	O
upsit	B-SMELL_TEST
score	O
using	O
the	O
same	O
model	O
the	O
results	O
of	O
this	O
study	O
provide	O
compelling	O
evidence	O
that	O
microstructural	O
degenerative	O
changes	O
in	O
these	O
areas	O
underlie	O
the	O
clinical	O
phenotype	O
of	O
prodromal	O
olfaction	O
dysfunction	O
in	O
pd	B-NEURODEGENERATIVE
and	O
that	O
diffusion	O
parameters	O
of	O
these	O
areas	O
might	O
be	O
able	O
to	O
serve	O
as	O
signature	O
markers	O
for	O
early	O
detection	O
of	O
pd	B-NEURODEGENERATIVE
this	O
is	O
the	O
first	O
report	O
that	O
confirms	O
a	O
discriminative	O
role	O
for	O
upsit	B-SMELL_TEST
score	O
in	O
identifying	O
pd	B-NEURODEGENERATIVE
specific	O
changes	O
in	O
white	O
matter	O
microstructure	O
our	O
results	O
open	O
a	O
window	O
to	O
identify	O
microstructural	O
signatures	O
of	O
prodromal	O
pd	B-NEURODEGENERATIVE
in	O
white	O
matter	O
selective	O
cognitive	O
and	O
psychiatric	O
manifestations	O
in	O
wolfram	O
syndrome	O
background	O
wolfram	O
syndrome	O
wfs	O
is	O
known	O
to	O
involve	O
diabetes	O
mellitus	O
diabetes	O
insipidus	O
optic	O
nerve	O
atrophy	O
vision	O
loss	O
hearing	O
impairment	O
motor	O
abnormalities	O
and	O
neurodegeneration	O
but	O
has	O
been	O
less	O
clearly	O
linked	O
to	O
cognitive	O
sleep	O
and	O
psychiatric	O
abnormalities	O
we	O
sought	O
to	O
determine	O
whether	O
these	O
abnormalities	O
are	O
present	O
in	O
children	O
adolescents	O
and	O
young	O
adults	O
with	O
wfs	O
compared	O
to	O
age	O
and	O
gendermatched	O
individuals	O
with	O
and	O
without	O
type	O
1	O
diabetes	O
using	O
standardized	O
measures	O
methods	O
individuals	O
with	O
geneticallyconfirmed	O
wfs	O
n	O
19	O
ages	O
727	O
were	O
compared	O
to	O
age	O
and	O
gender	O
equivalent	O
groups	O
of	O
individuals	O
with	O
type	O
1	O
diabetes	O
t1dm	O
n	O
25	O
and	O
nondiabetic	O
healthy	O
controls	O
hc	O
n	O
25	O
cognitive	O
performance	O
across	O
multiple	O
domains	O
verbal	O
intelligence	O
spatial	O
reasoning	O
memory	O
attention	O
smell	O
identification	O
was	O
assessed	O
using	O
standardized	O
tests	O
standardized	O
self	O
and	O
parentreport	O
questionnaires	O
on	O
psychiatric	O
symptoms	O
and	O
sleep	O
disturbances	O
were	O
acquired	O
from	O
all	O
groups	O
and	O
an	O
unstructured	O
psychiatric	O
interview	O
was	O
performed	O
within	O
only	O
the	O
wfs	O
group	O
results	O
the	O
three	O
groups	O
were	O
similar	O
demographically	O
age	O
gender	O
ethnicity	O
parental	O
iq	O
wfs	O
and	O
t1dm	O
had	O
similar	O
duration	O
of	O
diabetes	O
but	O
t1dm	O
had	O
higher	O
hba1c	O
levels	O
than	O
wfs	O
and	O
as	O
expected	O
both	O
groups	O
had	O
higher	O
levels	O
than	O
hc	O
the	O
wfs	O
group	O
was	O
impaired	O
on	O
smell	O
identification	O
and	O
reported	O
sleep	O
quality	O
but	O
was	O
not	O
impaired	O
in	O
any	O
other	O
cognitive	O
or	O
selfreported	O
psychiatric	O
domain	O
in	O
fact	O
the	O
wfs	O
group	O
performed	O
better	O
than	O
the	O
other	O
two	O
groups	O
on	O
selected	O
memory	O
and	O
attention	O
tasks	O
however	O
based	O
upon	O
a	O
clinical	O
evaluation	O
of	O
only	O
wfs	O
patients	B-PERCIEVER
we	O
found	O
that	O
psychiatric	O
and	O
behavioral	O
problems	O
were	O
present	O
and	O
consisted	O
primarily	O
of	O
anxiety	O
and	O
hypersomnolence	O
conclusions	O
this	O
study	O
found	O
that	O
cognitive	O
performance	O
and	O
psychological	O
health	O
were	O
relatively	O
preserved	O
wfs	O
patients	B-PERCIEVER
while	O
smell	O
and	O
sleep	O
abnormalities	O
manifested	O
in	O
many	O
of	O
the	O
wfs	O
patients	B-PERCIEVER
these	O
findings	O
contradict	O
past	O
case	O
and	O
retrospective	O
reports	O
indicating	O
significant	O
cognitive	O
and	O
psychiatric	O
impairment	O
in	O
wfs	O
while	O
many	O
of	O
these	O
patients	B-PERCIEVER
were	O
diagnosed	O
with	O
anxiety	O
and	O
hypersomnolence	O
selfreported	O
measures	O
of	O
psychiatric	O
symptoms	O
indicated	O
that	O
the	O
symptoms	O
were	O
not	O
of	O
grave	O
concern	O
to	O
the	O
patients	B-PERCIEVER
it	O
may	O
be	O
that	O
cognitive	O
and	O
psychiatric	O
issues	O
become	O
more	O
prominent	O
later	O
in	O
life	O
andor	O
in	O
later	O
stages	O
of	O
the	O
disease	O
but	O
this	O
requires	O
standardized	O
assessment	O
and	O
larger	O
samples	O
to	O
determine	O
in	O
the	O
relatively	O
early	O
stages	O
of	O
wfs	O
smell	O
and	O
sleeprelated	O
symptoms	O
may	O
be	O
useful	O
biomarkers	O
of	O
disease	O
and	O
should	O
be	O
monitored	O
longitudinally	O
to	O
determine	O
if	O
they	O
are	O
good	O
markers	O
of	O
progression	O
as	O
well	O
trial	O
registration	O
current	O
clinicaltrialsgov	O
trial	O
nct02455414	O
antioxidant	O
and	O
inflammatory	O
biomarkers	O
for	O
the	O
identification	O
of	O
prodromal	O
parkinsons	B-NEURODEGENERATIVE
disease	O
objectives	O
we	O
explored	O
the	O
role	O
of	O
oxidative	O
stress	O
and	O
inflammatory	O
molecules	O
as	O
potential	O
parkinson	B-NEURODEGENERATIVE
pd	B-NEURODEGENERATIVE
biomarkers	O
and	O
correlated	O
biological	O
with	O
nonmotor	O
abnormalities	O
olfactory	O
impairment	O
and	O
dysautonomia	O
in	O
patients	B-PERCIEVER
with	O
idiopathic	O
rem	O
behavior	O
disorder	O
irbd	O
prodromal	O
pd	B-NEURODEGENERATIVE
and	O
established	O
pd	B-NEURODEGENERATIVE
methods	O
we	O
recruited	O
11	O
irbd	O
and	O
15	O
patients	B-PERCIEVER
with	O
idiopathic	O
pd	B-NEURODEGENERATIVE
hohenyahr	O
13	O
on	O
ldopa	O
and	O
dopamine	O
agonists	O
combination	O
therapy	O
and	O
12	O
age	O
and	O
sexmatched	O
controls	O
ctrl	O
we	O
measured	O
total	O
olfactory	O
score	O
tos	O
autonomic	O
function	O
deep	O
breathing	O
db	O
lying	O
to	O
standing	O
ls	O
and	O
valsalva	O
manoeuvre	O
vm	O
ratios	O
blood	O
reduced	O
glutathione	O
brgsh	O
oxidative	O
stress	O
and	O
inflammatory	O
markers	O
neopterin	O
results	O
anosmia	B-OLFACTORY
was	O
similarly	O
prevalent	O
in	O
irbd	O
36	O
and	O
pd	B-NEURODEGENERATIVE
33	O
patients	B-PERCIEVER
but	O
absent	O
in	O
ctrl	O
orthostatic	O
hypotension	O
was	O
more	O
common	O
among	O
irbd	O
73	O
and	O
pd	B-NEURODEGENERATIVE
60	O
than	O
in	O
ctrl	O
25	O
by	O
univariable	O
ordinal	O
logistic	O
regression	O
tos	O
brgsh	O
ls	O
and	O
vm	O
ratio	O
worsened	O
from	O
ctrl	O
to	O
irbd	O
and	O
pd	B-NEURODEGENERATIVE
groups	O
only	O
reduced	O
brgsh	O
levels	O
p0037	O
or0994	O
95ci	O
09881000	O
were	O
independently	O
associated	O
to	O
pd	B-NEURODEGENERATIVE
tos	O
correlated	O
with	O
brgsh	O
r034	O
p0037	O
vm	O
ratio	O
r043	O
p0015	O
and	O
neopterin	O
rho039	O
p0016	O
conclusions	O
reduced	O
systemic	O
antioxidant	O
capacity	O
is	O
found	O
in	O
prodromal	O
and	O
overt	O
pd	B-NEURODEGENERATIVE
and	O
may	O
represent	O
in	O
association	O
with	O
olfactory	O
loss	O
and	O
cardiovascular	O
dysautonomia	O
a	O
useful	O
biomarker	O
for	O
an	O
integrative	O
early	O
diagnosis	O
of	O
pd	B-NEURODEGENERATIVE
olfactory	O
bulb	O
involvement	O
in	O
neurodegenerative	O
diseases	O
olfactory	O
dysfunction	O
is	O
a	O
common	O
and	O
early	O
symptom	O
of	O
many	O
neurodegenerative	O
diseases	O
particularly	O
of	O
parkinsons	B-NEURODEGENERATIVE
disease	O
and	O
other	O
synucleinopathies	O
alzheimers	B-NEURODEGENERATIVE
disease	O
ad	B-NEURODEGENERATIVE
and	O
mild	O
cognitive	O
impairment	O
heralding	O
its	O
progression	O
to	O
dementia	B-NEURODEGENERATIVE
the	O
neuropathologic	O
changes	O
of	O
olfactory	O
dysfunction	O
in	O
neurodegenerative	O
diseases	O
may	O
involve	O
the	O
olfactory	O
epithelium	O
olfactory	O
bulbtract	O
primary	O
olfactory	O
cortices	O
and	O
their	O
secondary	O
targets	O
olfactory	O
dysfunction	O
is	O
related	O
to	O
deposition	O
of	O
pathological	O
proteins	O
alphasynuclein	O
hyperphosphorylated	O
tau	O
protein	O
and	O
neurofilament	O
protein	O
in	O
these	O
areas	O
featured	O
by	O
neurofibrillary	O
tangles	O
lewy	O
bodies	O
and	O
neurites	O
inducing	O
a	O
complex	O
cascade	O
of	O
molecular	O
processes	O
including	O
oxidative	O
damage	O
neuroinflammation	O
and	O
cytosolic	O
disruption	O
of	O
cellular	O
processes	O
leading	O
to	O
cell	O
death	O
damage	O
to	O
cholinergic	O
serotonergic	O
and	O
noradrenergic	O
systems	O
is	O
likely	O
involved	O
since	O
such	O
damage	O
is	O
most	O
marked	O
in	O
those	O
diseases	O
with	O
severe	O
anosmia	B-OLFACTORY
recent	O
studies	O
of	O
olfactory	O
dysfunction	O
have	O
focused	O
its	O
potential	O
as	O
an	O
early	O
biomarker	O
for	O
the	O
diagnosis	O
of	O
neurodegenerative	O
disorders	O
and	O
their	O
disease	O
progression	O
here	O
we	O
summarize	O
the	O
current	O
knowledge	O
on	O
neuropathological	O
and	O
pathophysiological	O
changes	O
of	O
the	O
olfactory	O
system	O
in	O
the	O
most	O
frequent	O
neurodegenerative	O
diseases	O
in	O
particular	O
ad	B-NEURODEGENERATIVE
and	O
synucleinopathies	O
we	O
also	O
present	O
neuropathological	O
findings	O
in	O
the	O
olfactory	O
bulb	O
and	O
tract	O
in	O
a	O
large	O
autopsy	O
cohort	O
n	O
536	O
578	O
female	B-PERCIEVER
mean	O
age	O
813	O
years	O
the	O
severity	O
of	O
olfactory	O
bulb	O
hptau	O
abeta	O
and	O
alphasyn	O
pathology	O
correlated	O
and	O
increased	O
significantly	O
p	O
0001	O
with	O
increasing	O
neuritic	O
braak	O
stages	O
thal	O
abeta	O
phases	O
and	O
cerebral	O
lewy	O
body	O
pathology	O
respectively	O
hence	O
further	O
studies	O
are	O
warranted	O
to	O
investigate	O
the	O
potential	O
role	O
of	O
olfactory	O
biopsies	O
possibly	O
restricted	O
to	O
the	O
olfactory	O
epithelium	O
in	O
the	O
diagnostic	O
process	O
of	O
neurodegenerative	O
diseases	O
in	O
particular	O
in	O
clinical	O
drug	O
trials	O
to	O
identify	O
subjects	B-PERCIEVER
showing	O
early	O
preclinical	O
stages	O
of	O
neurodegeneration	O
and	O
to	O
stratify	O
clinically	O
impaired	O
cohorts	O
according	O
to	O
the	O
underlying	O
cerebral	O
neuropathology	O
potential	O
convergence	O
of	O
olfactory	O
dysfunction	O
in	O
parkinsons	B-NEURODEGENERATIVE
disease	O
and	O
covid19	O
the	O
role	O
of	O
neuroinflammation	O
parkinsons	B-NEURODEGENERATIVE
disease	O
pd	B-NEURODEGENERATIVE
is	O
a	O
prevalent	O
neurodegenerative	O
disorder	O
that	O
affects	O
710	O
million	O
individuals	O
worldwide	O
a	O
common	O
early	O
symptom	O
of	O
pd	B-NEURODEGENERATIVE
is	O
olfactory	O
dysfunction	O
od	O
and	O
more	O
than	O
90	O
of	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
suffer	O
from	O
od	O
recent	O
studies	O
have	O
highlighted	O
a	O
high	O
incidence	O
of	O
od	O
in	O
patients	B-PERCIEVER
with	O
sarscov2	O
infection	O
this	O
review	O
investigates	O
the	O
potential	O
convergence	O
of	O
od	O
in	O
pd	B-NEURODEGENERATIVE
and	O
covid19	O
particularly	O
focusing	O
on	O
the	O
mechanisms	O
by	O
which	O
neuroinflammation	O
contributes	O
to	O
od	O
and	O
neurological	O
events	O
starting	O
from	O
our	O
fundamental	O
understanding	O
of	O
the	O
olfactory	O
bulb	O
we	O
summarize	O
the	O
clinical	O
features	O
of	O
od	O
and	O
pathological	O
features	O
of	O
the	O
olfactory	O
bulb	O
from	O
clinical	O
cases	O
and	O
autopsy	O
reports	O
in	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
we	O
then	O
examine	O
sarscov2induced	O
olfactory	O
bulb	O
neuropathology	O
and	O
od	O
and	O
emphasize	O
the	O
sarscov2induced	O
neuroinflammatory	O
cascades	O
potentially	O
leading	O
to	O
pd	B-NEURODEGENERATIVE
manifestations	O
by	O
activating	O
microglia	O
and	O
astrocytes	O
as	O
well	O
as	O
facilitating	O
the	O
aggregation	O
of	O
alphasynuclein	O
sarscov2	O
could	O
contribute	O
to	O
the	O
onset	O
or	O
exacerbation	O
of	O
pd	B-NEURODEGENERATIVE
we	O
also	O
discuss	O
the	O
possible	O
contributions	O
of	O
nfkappab	O
the	O
nlrp3	O
inflammasome	O
and	O
the	O
jakstat	O
p38	O
mapk	O
tlr4	O
il6jak2stat3	O
and	O
cgassting	O
signaling	O
pathways	O
although	O
olfactory	O
dysfunction	O
in	O
patients	B-PERCIEVER
with	O
covid19	O
may	O
be	O
reversible	O
it	O
is	O
challenging	O
to	O
restore	O
od	O
in	O
patients	B-PERCIEVER
with	O
pd	B-NEURODEGENERATIVE
with	O
the	O
emergence	O
of	O
new	O
sarscov2	O
variants	O
and	O
the	O
recurrence	O
of	O
infections	O
we	O
call	O
for	O
continued	O
attention	O
to	O
the	O
intersection	O
between	O
pd	B-NEURODEGENERATIVE
and	O
sarscov2	O
infection	O
especially	O
from	O
the	O
perspective	O
of	O
od	O
diagnostic	O
accuracy	O
item	O
analysis	O
and	O
age	O
effects	O
of	O
the	O
upsit	B-SMELL_TEST
spanish	O
version	O
in	O
parkinsons	B-NEURODEGENERATIVE
disease	O
objective	O
the	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O
upsit	B-SMELL_TEST
is	O
the	O
most	O
commonly	O
used	O
test	O
to	O
detect	O
olfactory	O
impairment	O
in	O
parkinsons	B-NEURODEGENERATIVE
disease	O
pd	B-NEURODEGENERATIVE
but	O
the	O
cutoff	O
score	O
for	O
clinical	O
purposes	O
is	O
often	O
difficult	O
to	O
establish	O
because	O
of	O
age	O
and	O
sex	O
effects	O
the	O
current	O
work	O
aims	O
to	O
study	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
upsit	B-SMELL_TEST
spanish	O
version	O
and	O
its	O
accuracy	O
in	O
discriminating	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
at	O
different	O
age	O
groups	O
from	O
healthy	O
controls	O
hc	O
and	O
to	O
perform	O
an	O
item	O
analysis	O
method	O
ninetyseven	O
nondemented	O
pd	B-NEURODEGENERATIVE
patients	B-PERCIEVER
and	O
65	O
hc	O
were	O
assessed	O
with	O
the	O
upsit	B-SMELL_TEST
spanish	O
version	O
sensitivity	O
specificity	O
and	O
diagnostic	O
accuracy	O
for	O
pd	B-NEURODEGENERATIVE
were	O
calculated	O
multiple	O
regression	O
analysis	O
was	O
used	O
to	O
define	O
predictors	O
of	O
upsit	B-SMELL_TEST
scores	O
results	O
using	O
the	O
normative	O
cutoff	O
score	O
for	O
anosmia	B-OLFACTORY
18	O
the	O
upsit	B-SMELL_TEST
showed	O
a	O
sensitivity	O
of	O
546	O
with	O
a	O
specificity	O
of	O
1000	O
for	O
pd	B-NEURODEGENERATIVE
we	O
found	O
that	O
using	O
the	O
upsit	B-SMELL_TEST
cutoff	O
score	O
of	O
25	O
sensitivity	O
was	O
814	O
and	O
specificity	O
846	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
0908	O
diagnosis	O
and	O
age	O
were	O
good	O
predictors	O
of	O
upsit	B-SMELL_TEST
scores	O
b	O
10948	O
p	O
001	O
b	O
0203	O
p	O
001	O
when	O
optimal	O
cutoff	O
scores	O
were	O
considered	O
according	O
to	O
age	O
ranges	O
60	O
6170	O
and	O
71	O
sensitivity	O
and	O
specificity	O
values	O
were	O
800	O
for	O
all	O
age	O
groups	O
conclusions	O
in	O
the	O
spanish	O
upsit	B-SMELL_TEST
version	O
sensitivity	O
and	O
specificity	O
are	O
improved	O
when	O
specific	O
cutoff	O
scores	O
for	O
different	O
age	O
groups	O
are	O
computed	O
anosmia	B-OLFACTORY
in	O
dementia	B-NEURODEGENERATIVE
is	O
associated	O
with	O
lewy	O
bodies	O
rather	O
than	O
alzheimers	B-NEURODEGENERATIVE
pathology	O
covid19	O
and	O
olfactory	O
dysfunction	O
a	O
looming	O
wave	O
of	O
dementia	B-NEURODEGENERATIVE
olfactory	O
dysfunction	O
is	O
a	O
hallmark	O
symptom	O
of	O
covid19	O
disease	O
resulting	O
from	O
the	O
sarscov2	O
virus	O
the	O
cause	O
of	O
the	O
sudden	O
and	O
usually	O
temporary	O
anosmia	B-OLFACTORY
that	O
most	O
people	O
suffer	O
from	O
covid19	O
is	O
likely	O
entirely	O
peripheralinflammation	O
and	O
other	O
damage	O
caused	O
by	O
the	O
virus	O
in	O
the	O
sensory	O
epithelium	O
inside	O
the	O
upper	O
recesses	O
of	O
the	O
nasal	O
cavity	O
can	O
damage	O
or	O
prevent	O
chemicals	O
from	O
properly	O
activating	O
the	O
olfactory	O
sensory	O
neurons	O
however	O
persistent	O
olfactory	O
dysfunction	O
from	O
covid19	O
in	O
the	O
form	O
of	O
hyposmia	B-OLFACTORY
and	O
parosmia	B-OLFACTORY
decreased	O
or	O
altered	O
smell	O
may	O
affect	O
as	O
many	O
as	O
15	O
million	O
people	O
worldwide	O
this	O
epidemic	O
of	O
olfactory	O
dysfunction	O
is	O
thus	O
a	O
continuing	O
public	O
health	O
concern	O
mounting	O
evidence	O
suggests	O
that	O
the	O
sarscov2	O
virus	O
itself	O
or	O
inflammation	O
from	O
the	O
immune	O
response	O
in	O
the	O
nasal	O
sensory	O
epithelium	O
may	O
invade	O
the	O
olfactory	O
bulb	O
likely	O
via	O
nonneuronal	O
transmission	O
covid19related	O
longterm	O
olfactory	O
dysfunction	O
and	O
early	O
damage	O
to	O
olfactory	O
and	O
limbic	O
brain	O
regions	O
suggest	O
a	O
pattern	O
of	O
degeneration	O
similar	O
to	O
that	O
seen	O
in	O
early	O
stages	O
of	O
alzheimers	B-NEURODEGENERATIVE
disease	O
parkinsons	B-NEURODEGENERATIVE
disease	O
and	O
lewy	O
body	O
dementia	B-NEURODEGENERATIVE
thus	O
longterm	O
olfactory	O
dysfunction	O
coupled	O
with	O
cognitive	O
and	O
emotional	O
disturbance	O
from	O
covid19	O
may	O
be	O
the	O
first	O
signs	O
of	O
delayed	O
onset	O
dementia	B-NEURODEGENERATIVE
from	O
neurodegeneration	O
few	O
treatments	O
are	O
known	O
to	O
be	O
effective	O
to	O
prevent	O
further	O
degeneration	O
but	O
the	O
first	O
line	O
of	O
defense	O
against	O
degeneration	O
may	O
be	O
olfactory	O
and	O
environmental	O
enrichment	O
there	O
is	O
a	O
pressing	O
need	O
for	O
more	O
research	O
on	O
treatments	O
for	O
olfactory	O
dysfunction	O
and	O
longitudinal	O
studies	O
including	O
cognitive	O
and	O
olfactory	O
function	O
from	O
patients	B-PERCIEVER
who	O
have	O
recovered	O
from	O
even	O
mild	O
covid19new	O
noteworthy	O
more	O
than	O
15	O
million	O
people	O
worldwide	O
experience	O
persistent	O
covid19	O
olfactory	O
dysfunction	O
possibly	O
caused	O
by	O
olfactory	O
bulb	O
damage	O
sarscov2	O
can	O
cause	O
inflammation	O
and	O
viral	O
invasion	O
of	O
the	O
olfactory	O
bulb	O
initiating	O
a	O
cascade	O
of	O
degeneration	O
similar	O
to	O
alzheimers	B-NEURODEGENERATIVE
disease	O
and	O
lewy	O
body	O
disease	O
people	O
who	O
have	O
had	O
even	O
mild	O
cases	O
of	O
covid19	O
show	O
signs	O
of	O
degeneration	O
in	O
cortical	O
areas	O
connected	O
with	O
the	O
olfactory	O
system	O
these	O
data	O
suggest	O
a	O
wave	O
of	O
postcovid	O
dementia	B-NEURODEGENERATIVE
in	O
the	O
coming	O
decades	O
anosmia	B-OLFACTORY
is	O
very	O
common	O
in	O
the	O
lewy	O
body	O
variant	O
of	O
alzheimers	B-NEURODEGENERATIVE
disease	O
background	O
olfactory	O
abnormalities	O
are	O
reported	O
in	O
alzheimers	B-NEURODEGENERATIVE
disease	O
and	O
parkinsons	B-NEURODEGENERATIVE
disease	O
anosmia	B-OLFACTORY
appears	O
to	O
be	O
common	O
in	O
dementia	B-NEURODEGENERATIVE
with	O
lewy	O
bodies	O
but	O
not	O
in	O
pure	O
alzheimers	B-NEURODEGENERATIVE
disease	O
objective	O
to	O
determine	O
whether	O
anosmia	B-OLFACTORY
improves	O
discrimination	O
between	O
the	O
lewy	O
body	O
variant	O
lbv	O
of	O
alzheimers	B-NEURODEGENERATIVE
disease	O
and	O
pure	O
alzheimers	B-NEURODEGENERATIVE
disease	O
methods	O
106	O
cases	O
of	O
necropsy	O
confirmed	O
pure	O
alzheimers	B-NEURODEGENERATIVE
disease	O
n	O
89	O
or	O
lbv	O
n	O
17	O
were	O
reviewed	O
all	O
had	O
received	O
butanol	O
odour	O
threshold	O
testing	O
anosmia	B-OLFACTORY
was	O
defined	O
as	O
a	O
score	O
or	O
10	O
on	O
a	O
09	O
point	O
scale	O
logistic	O
regression	O
analysis	O
was	O
used	O
to	O
model	O
potential	O
predictors	O
for	O
example	O
parkinsonism	O
smoking	O
hallucinations	O
of	O
neuropathological	O
diagnosis	O
and	O
anosmia	B-OLFACTORY
results	O
lbv	O
cases	O
had	O
an	O
increased	O
prevalence	O
of	O
anosmia	B-OLFACTORY
65	O
compared	O
with	O
alzheimers	B-NEURODEGENERATIVE
disease	O
23	O
odds	O
ratio	O
or	O
63	O
p	O
000045	O
or	O
normal	O
elderly	O
people	O
67	O
within	O
the	O
dementia	B-NEURODEGENERATIVE
cases	O
the	O
negative	O
predictive	O
value	O
92	O
and	O
specificity	O
78	O
of	O
anosmia	B-OLFACTORY
were	O
both	O
good	O
sensitivity	O
for	O
detecting	O
lbv	O
was	O
65	O
but	O
the	O
positive	O
predictive	O
value	O
ppv	O
was	O
only	O
35	O
logistic	O
regression	O
models	O
showed	O
anosmia	B-OLFACTORY
or	O
54	O
p	O
0005	O
and	O
visual	O
hallucinations	O
or	O
73	O
p	O
0007	O
were	O
strong	O
independent	O
predictors	O
of	O
lewy	O
body	O
pathology	O
when	O
anosmia	B-OLFACTORY
was	O
added	O
as	O
a	O
core	O
feature	O
to	O
consensus	O
diagnostic	O
criteria	O
for	O
probable	O
lewy	O
body	O
dementia	B-NEURODEGENERATIVE
five	O
additional	O
cases	O
of	O
lbv	O
were	O
detected	O
29	O
increased	O
sensitivity	O
but	O
with	O
four	O
additional	O
false	O
positives	O
1	O
increased	O
discrimination	O
4	O
decreased	O
specificity	O
33	O
decreased	O
ppv	O
conclusions	O
anosmia	B-OLFACTORY
is	O
very	O
common	O
in	O
lbv	O
adding	O
anosmia	B-OLFACTORY
as	O
a	O
core	O
feature	O
improved	O
sensitivity	O
for	O
detecting	O
lbv	O
but	O
did	O
not	O
improve	O
discrimination	O
between	O
alzheimers	B-NEURODEGENERATIVE
disease	O
and	O
lbv	O
owing	O
to	O
a	O
concomitant	O
increase	O
in	O
false	O
positives	O
association	O
of	O
anosmia	B-OLFACTORY
with	O
autonomic	O
failure	O
in	O
parkinson	B-NEURODEGENERATIVE
disease	O
background	O
olfactory	O
dysfunction	O
and	O
autonomic	O
failure	O
are	O
gaining	O
recognition	O
as	O
nonmotor	O
manifestations	O
of	O
parkinson	B-NEURODEGENERATIVE
disease	O
pd	B-NEURODEGENERATIVE
this	O
observational	O
study	O
assessed	O
whether	O
in	O
pd	B-NEURODEGENERATIVE
anosmia	B-OLFACTORY
and	O
autonomic	O
failure	O
are	O
related	O
to	O
each	O
other	O
or	O
to	O
neuroimaging	O
evidence	O
of	O
striatal	O
dopamine	O
deficiency	O
methods	O
olfactory	O
function	O
was	O
assessed	O
by	O
the	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O
upsit	B-SMELL_TEST
in	O
23	O
patients	B-PERCIEVER
with	O
sporadic	O
pd	B-NEURODEGENERATIVE
baroreflexcardiovagal	O
gain	O
was	O
quantified	O
from	O
the	O
relationship	O
between	O
cardiac	O
interbeat	O
interval	O
and	O
systolic	O
pressure	O
during	O
the	O
valsalva	O
maneuver	O
and	O
baroreflexsympathoneural	O
function	O
by	O
responses	O
of	O
systolic	O
pressure	O
to	O
the	O
valsalva	O
maneuver	O
and	O
of	O
hemodynamics	O
and	O
plasma	O
norepinephrine	O
ne	O
and	O
dihydroxyphenylglycol	O
dhpg	O
levels	O
to	O
orthostasis	O
618ffluorodopamine	O
pet	O
and	O
plasma	O
and	O
skeletal	O
muscle	O
microdialysate	O
ne	O
and	O
dhpg	O
were	O
used	O
to	O
indicate	O
cardiac	O
and	O
extracardiac	O
noradrenergic	O
innervation	O
and	O
brain	O
618ffluorodopa	O
pet	O
to	O
indicate	O
striatal	O
dopaminergic	O
innervation	O
parkinsonism	O
was	O
assessed	O
by	O
updrs	O
scores	O
results	O
compared	O
to	O
patients	B-PERCIEVER
with	O
pd	B-NEURODEGENERATIVE
and	O
normal	O
to	O
moderately	O
decreased	O
sense	O
of	O
smell	O
patients	B-PERCIEVER
with	O
anosmic	O
pd	B-NEURODEGENERATIVE
had	O
lower	O
mean	O
baroreflexcardiovagal	O
gain	O
p	O
004	O
larger	O
falls	O
in	O
systolic	O
pressure	O
during	O
the	O
valsalva	O
maneuver	O
and	O
orthostasis	O
p	O
004	O
p	O
002	O
smaller	O
orthostatic	O
increments	O
in	O
plasma	O
ne	O
and	O
dhpg	O
p	O
0003	O
p	O
003	O
lower	O
cardiac	O
septalhepatic	O
and	O
renal	O
corticalhepatic	O
ratios	O
of	O
618ffluorodopaminederived	O
radioactivity	O
p	O
001	O
p	O
006	O
and	O
lower	O
microdialysate	O
ne	O
and	O
dhpg	O
p	O
001	O
p	O
0006	O
neither	O
clinical	O
severity	O
of	O
parkinsonism	O
nor	O
the	O
putamenoccipital	O
cortex	O
ratio	O
of	O
618ffluorodopaderived	O
radioactivity	O
was	O
related	O
to	O
the	O
upsit	B-SMELL_TEST
category	O
conclusions	O
in	O
parkinson	B-NEURODEGENERATIVE
disease	O
anosmia	B-OLFACTORY
is	O
associated	O
with	O
baroreflex	O
failure	O
and	O
cardiac	O
and	O
organselective	O
extracardiac	O
noradrenergic	O
denervation	O
independently	O
of	O
parkinsonism	O
or	O
striatal	O
dopaminergic	O
denervation	O
